5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
| Title | Journal |
|---|---|
| Why are most phospholipidosis inducers also hERG blockers? | Archives of toxicology 20171201 |
| Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20140901 |
| A high-throughput screen for teratogens using human pluripotent stem cells. | Toxicological sciences : an official journal of the Society of Toxicology 20140101 |
| Reduction and methylation of ziprasidone by glutathione, aldehyde oxidase, and thiol S-methyltransferase in humans: an in vitro study. | Xenobiotica; the fate of foreign compounds in biological systems 20121101 |
| Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone. | Neuroscience letters 20121024 |
| New treatment guidelines for acute bipolar mania: a critical review. | Journal of affective disorders 20121001 |
| Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle cerebral artery occlusion in rats. | Progress in neuro-psychopharmacology & biological psychiatry 20121001 |
| Lurasidone in schizophrenia: new information about dosage and place in therapy. | Advances in therapy 20121001 |
| A case of severe hyponatremia induced by duloxetine and ziprasidone. | Chinese medical journal 20121001 |
| Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. | Experimental & molecular medicine 20120930 |
| Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. | Journal of psychopharmacology (Oxford, England) 20120901 |
| Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. | Biopharmaceutics & drug disposition 20120901 |
| Serotonin 1A receptors in the action of antipsychotic drugs: comment on 'Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone' by Frankle et al. 2011; 25(6): 734-743. | Journal of psychopharmacology (Oxford, England) 20120901 |
| Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. | Expert opinion on drug safety 20120901 |
| A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report. | Innovations in clinical neuroscience 20120901 |
| A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. | Expert opinion on pharmacotherapy 20120801 |
| Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? | Journal of clinical psychopharmacology 20120801 |
| Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. | Schizophrenia bulletin 20120701 |
| Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study. | Pharmacopsychiatry 20120701 |
| The treatment of hallucinations in schizophrenia spectrum disorders. | Schizophrenia bulletin 20120701 |
| Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. | International clinical psychopharmacology 20120701 |
| Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. | Postgraduate medicine 20120701 |
| Single-dose ziprasidone associated with QT interval prolongation. | The American journal of emergency medicine 20120601 |
| The effect of ziprasidone on body weight and energy expenditure in female rats. | Metabolism: clinical and experimental 20120601 |
| Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. | Pharmacopsychiatry 20120601 |
| Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST. | Schizophrenia research 20120601 |
| Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. | Journal of clinical psychopharmacology 20120601 |
| A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone. | Journal of clinical psychopharmacology 20120601 |
| Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? | CNS drugs 20120601 |
| Rash in psychiatric and nonpsychiatric adolescent patients receiving lamotrigine in Korea: a retrospective cohort study. | Psychiatry investigation 20120601 |
| Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. | Journal of managed care pharmacy : JMCP 20120601 |
| Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. | The Journal of clinical psychiatry 20120601 |
| In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. | International journal of pharmaceutics 20120530 |
| Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120501 |
| Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. | Schizophrenia research 20120501 |
| Maintenance therapies in bipolar disorders. | Bipolar disorders 20120501 |
| Network-assisted investigation of antipsychotic drugs and their targets. | Chemistry & biodiversity 20120501 |
| The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. | The Journal of clinical psychiatry 20120401 |
| The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. | Journal of clinical psychopharmacology 20120401 |
| Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. | CNS drugs 20120401 |
| Automatic filtering and substantiation of drug safety signals. | PLoS computational biology 20120401 |
| Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). | Cutis 20120401 |
| Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies. | International journal of psychiatry in clinical practice 20120301 |
| Adolescent female with withdrawal psychosis following abrupt termination of ziprasidone. | European child & adolescent psychiatry 20120301 |
| The pharmacogenetics of symptom response to antipsychotic drugs. | Psychiatry investigation 20120301 |
| Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20120301 |
| Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version). | East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan 20120301 |
| Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. | PLoS medicine 20120301 |
| Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot. | Innovations in clinical neuroscience 20120301 |
| Assessment of the stability of 30 antipsychotic drugs in stored blood specimens. | Forensic science international 20120210 |
| Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. | Psychopharmacology 20120201 |
| Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120201 |
| The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients. | Psychopharmacology 20120201 |
| Sensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis. | Schizophrenia research 20120201 |
| Mixed depression: a study of its phenomenology and relation to treatment response. | Journal of affective disorders 20120201 |
| The role of antipsychotics in the management of fibromyalgia. | CNS drugs 20120201 |
| Antipsychotic-induced psychotic-like syndrome and pathological smiling in an adolescent. | Journal of child and adolescent psychopharmacology 20120201 |
| The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. | The western journal of emergency medicine 20120201 |
| The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. | Psychiatry research 20120130 |
| Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. | Schizophrenia bulletin 20120101 |
| Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. | Schizophrenia bulletin 20120101 |
| Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. | CNS neuroscience & therapeutics 20120101 |
| Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. | Comprehensive psychiatry 20120101 |
| Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. | Journal of affective disorders 20120101 |
| Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia. | Journal of medical economics 20120101 |
| Atypical antipsychotic drugs and ethanol withdrawal syndrome: a review. | Alcohol and alcoholism (Oxford, Oxfordshire) 20120101 |
| Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. | Human psychopharmacology 20120101 |
| Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia. | Clinical schizophrenia & related psychoses 20120101 |
| Do we really know how to treat a child with bipolar disorder or one with severe mood dysregulation? Is there a magic bullet? | Depression research and treatment 20120101 |
| The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease. | Parkinson's disease 20120101 |
| Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101 |
| Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. | Patient preference and adherence 20120101 |
| Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. | BMJ (Clinical research ed.) 20120101 |
| Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients. | Behavioral and brain functions : BBF 20120101 |
| Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression. | Frontiers in psychiatry 20120101 |
| Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. | Clinical neuropharmacology 20120101 |
| Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. | Journal of affective disorders 20120101 |
| Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model. | Journal of neuroinflammation 20120101 |
| Update on the role of antipsychotics in the treatment of Tourette syndrome. | Neuropsychiatric disease and treatment 20120101 |
| Genome-wide association study of treatment refractory schizophrenia in Han Chinese. | PloS one 20120101 |
| The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors. | Journal of obesity 20120101 |
| A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. | PloS one 20120101 |
| Three key antipsychotics lose patent protection. | Behavioral healthcare 20120101 |
| Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics. | PloS one 20120101 |
| Desipramine inhibits histamine H1 receptor-induced Ca2+ signaling in rat hypothalamic cells. | PloS one 20120101 |
| Critical appraisal of lurasidone in the management of schizophrenia. | Neuropsychiatric disease and treatment 20120101 |
| Heart rate-corrected QT interval helps predict mortality after intentional organophosphate poisoning. | PloS one 20120101 |
| Antidopaminergic drugs and acute pancreatitis: a population-based study. | BMJ open 20120101 |
| Sudden death of cardiac origin and psychotropic drugs. | Frontiers in pharmacology 20120101 |
| Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. | Clinical neuropharmacology 20120101 |
| Development and validation of an automated high-throughput system for zebrafish in vivo screenings. | PloS one 20120101 |
| Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade. | Frontiers in psychiatry 20120101 |
| Treatment-resistant Schizophrenia: Evidence-based Strategies. | Mens sana monographs 20120101 |
| Treatment-resistant depression: therapeutic trends, challenges, and future directions. | Patient preference and adherence 20120101 |
| Update on the development of lurasidone as a treatment for patients with acute schizophrenia. | Drug design, development and therapy 20120101 |
| High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. | Journal of chromatographic science 20120101 |
| Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia. | Depression research and treatment 20120101 |
| Altered velocity processing in schizophrenia during pursuit eye tracking. | PloS one 20120101 |
| Role of aripiprazole in treatment-resistant schizophrenia. | Neuropsychiatric disease and treatment 20120101 |
| The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder. | The Israel journal of psychiatry and related sciences 20120101 |
| Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey. | Health and quality of life outcomes 20120101 |
| Ziprasidone in the treatment of delusional parasitosis. | Case reports in dermatology 20120101 |
| Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. | Pharmacological reports : PR 20120101 |
| Prediction of chemical-protein interactions network with weighted network-based inference method. | PloS one 20120101 |
| Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. | BMC psychiatry 20120101 |
| Tianeptine in combination with monoamine oxidase inhibitors for major depressive disorder. | BMJ case reports 20120101 |
| Development of rapid and robust stability-indicating method for analysis of ziprasidone (hydrochloride and freebase) as drug substance and in medicines by UPLC. | Acta poloniae pharmaceutica 20120101 |
| Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia. | The primary care companion for CNS disorders 20120101 |
| Review of the safety of second-generation antipsychotics: are they really 'atypically' safe for youth and adults? | The primary care companion for CNS disorders 20120101 |
| Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. | Biomedical chromatography : BMC 20111201 |
| Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. | Pharmaceutical research 20111201 |
| Effect of cryogrinding on chemical stability of the sparingly water-soluble drug furosemide. | Pharmaceutical research 20111201 |
| Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. | Xenobiotica; the fate of foreign compounds in biological systems 20111201 |
| Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. | Progress in neuro-psychopharmacology & biological psychiatry 20111201 |
| Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. | Schizophrenia research 20111201 |
| Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. | Clinical therapeutics 20111201 |
| Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. | Journal of child and adolescent psychopharmacology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. | The Journal of clinical psychiatry 20111201 |
| Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. | Journal of clinical pharmacology 20111101 |
| Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC). | Pharmacoepidemiology and drug safety 20111101 |
| Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia. | Schizophrenia research 20111101 |
| Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. | Schizophrenia research 20111101 |
| Lurasidone: a new treatment option for schizophrenia. | Drugs of today (Barcelona, Spain : 1998) 20111101 |
| Calculated carbon-hydrogen bond dissociation enthalpies for predicting oxidative susceptibility of drug substance molecules. | International journal of pharmaceutics 20111014 |
| Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. | Lancet (London, England) 20111008 |
| Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. | The Journal of clinical psychiatry 20111001 |
| Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. | Expert opinion on pharmacotherapy 20111001 |
| Probable quetiapine-mediated prolongation of the QT interval. | Journal of pharmacy practice 20111001 |
| Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report. | Journal of clinical psychopharmacology 20111001 |
| Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. | Paediatric drugs 20111001 |
| Predicting psychiatric hospital admission among adults with schizophrenia. | Psychiatric services (Washington, D.C.) 20111001 |
| QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. | Deutsches Arzteblatt international 20111001 |
| Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. | JAMA 20110928 |
| Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. | The international journal of neuropsychopharmacology 20110901 |
| Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. | The international journal of neuropsychopharmacology 20110901 |
| Ziprasidone induced symptomatic bradycardia: a case report. | The Australian and New Zealand journal of psychiatry 20110901 |
| Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. | Psychiatric services (Washington, D.C.) 20110901 |
| Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials. | Pharmacotherapy 20110901 |
| Effect of initial ziprasidone dose on treatment outcome of korean patients with acute manic or mixed episodes. | Psychiatry investigation 20110901 |
| Antidepressant prescribing patterns in Korea: results from the clinical research center for depression study. | Psychiatry investigation 20110901 |
| Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. | Journal of psychiatric research 20110801 |
| Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. | Psychopharmacology 20110801 |
| Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. | Drug safety 20110801 |
| Outcome assessment of an antipsychotic drug algorithm: effects of the Mississippi State Hospital algorithm project. | Psychiatric services (Washington, D.C.) 20110801 |
| Digital Holter measurement of QT prolongation in ziprasidone overdose. | Clinical toxicology (Philadelphia, Pa.) 20110801 |
| Relationship between P-glycoprotein and second-generation antipsychotics. | Pharmacogenomics 20110801 |
| Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. | Journal of psychopharmacology (Oxford, England) 20110701 |
| Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. | American journal of therapeutics 20110701 |
| Molecular dynamics of the cryomilled base and hydrochloride ziprasidones by means of dielectric spectroscopy. | Journal of pharmaceutical sciences 20110701 |
| Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone. | Journal of pharmaceutical sciences 20110701 |
| Stability-indicating spectrofluorimetric method for the assay of ziprasidone in capsules. | Journal of fluorescence 20110701 |
| Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. | Psychopharmacology 20110701 |
| A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. | Progress in neuro-psychopharmacology & biological psychiatry 20110701 |
| Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial. | Pharmacopsychiatry 20110701 |
| Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). | The Journal of clinical psychiatry 20110701 |
| Psychosis in Parkinson's disease. | Annals of Indian Academy of Neurology 20110701 |
| Dementia in parkinsonism. | Annals of Indian Academy of Neurology 20110701 |
| Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus. | Pediatric reports 20110630 |
| Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone. | Journal of psychopharmacology (Oxford, England) 20110601 |
| Antipsychotic drug use and community-acquired pneumonia. | Current infectious disease reports 20110601 |
| QT interval duration and dispersion in children and adolescents treated with ziprasidone. | The Journal of clinical psychiatry 20110601 |
| Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. | Journal of clinical psychopharmacology 20110601 |
| Adverse effects of oral nonstimulant psychotropic medications in young children reported to a regional poison center. | Clinical toxicology (Philadelphia, Pa.) 20110601 |
| Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study. | The American journal of psychiatry 20110601 |
| Quality of life after electroconvulsive therapy in persons with treatment resistant schizophrenia. | The Indian journal of medical research 20110601 |
| A case of catatonia and neuroleptic malignant syndrome probably associated with antipsychotic in Korea. | Psychiatry investigation 20110601 |
| Oxidative stress in schizophrenia. | Current neuropharmacology 20110601 |
| Effect of antipsychotic medications on glucose and lipid levels. | Journal of clinical pharmacology 20110501 |
| Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. | Journal of psychopharmacology (Oxford, England) 20110501 |
| A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. | International clinical psychopharmacology 20110501 |
| Drug safety evaluation of ziprasidone. | Expert opinion on drug safety 20110501 |
| The association between weight change and symptom reduction in the CATIE schizophrenia trial. | Schizophrenia research 20110501 |
| The safety of atypical antipsychotics: does QTc provide all the answers? | Expert opinion on drug safety 20110501 |
| Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20110501 |
| Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. | PLoS medicine 20110501 |
| Psychosis in Parkinson's disease: therapeutic options. | Drugs of today (Barcelona, Spain : 1998) 20110501 |
| Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. | Neuroscience research 20110401 |
| Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. | Schizophrenia research 20110401 |
| Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. | European psychiatry : the journal of the Association of European Psychiatrists 20110401 |
| Ziprasidone for maintenance treatment of bipolar I disorder in adults. | Expert opinion on pharmacotherapy 20110401 |
| European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. | European child & adolescent psychiatry 20110401 |
| Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. | PLoS medicine 20110401 |
| Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services. | The Journal of clinical psychiatry 20110401 |
| Newer molecules in the treatment of schizophrenia: A clinical update. | Indian journal of pharmacology 20110401 |
| Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats. | Progress in neuro-psychopharmacology & biological psychiatry 20110330 |
| A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. | Journal of medicinal chemistry 20110324 |
| Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. | Schizophrenia bulletin 20110301 |
| Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. | The Journal of clinical psychiatry 20110301 |
| Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. | International clinical psychopharmacology 20110301 |
| Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. | Schizophrenia research 20110301 |
| Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. | European child & adolescent psychiatry 20110301 |
| Corrected QT interval changes during electroconvulsive therapy-antidepressants-atypical antipsychotics coadministration: safety issues. | The journal of ECT 20110301 |
| Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. | Journal of psychiatric practice 20110301 |
| Use of ziprasidone in patients with schizophrenia in four European countries. | European psychiatry : the journal of the Association of European Psychiatrists 20110301 |
| Switching among antipsychotics--focus on side effects. | Psychiatria Danubina 20110301 |
| Antipsychotic treatment--side-effect and/or metabolic syndrome. | Psychiatria Danubina 20110301 |
| Weight gain--as possible predictor of metabolic syndrome. | Psychiatria Danubina 20110301 |
| Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone. | The Journal of clinical psychiatry 20110301 |
| Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20110301 |
| Iloperidone for the management of adults with schizophrenia. | Clinical therapeutics 20110301 |
| Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. | Expert review of clinical pharmacology 20110301 |
| Metabolic profile of first and second generation antipsychotics among Chinese patients. | Psychiatry research 20110227 |
| Iloperidone: A new drug for the treatment of schizophrenia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110215 |
| Third degree heart block following intramuscular ziprasidone. | Schizophrenia research 20110201 |
| Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). | The American journal of psychiatry 20110201 |
| Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20110201 |
| Ziprasidone and the relative risk of diabetes. | The British journal of psychiatry : the journal of mental science 20110201 |
| What can large simple trials do for psychiatry? | The American journal of psychiatry 20110201 |
| The role of serotonin receptors in the action of atypical antipsychotic drugs. | Current opinion in pharmacology 20110201 |
| Adverse drug reaction monitoring in psychiatry out-patient department of an Indian teaching hospital. | Indian journal of pharmacology 20110201 |
| Management of schizophrenia in children and adolescents: focus on pharmacotherapy. | Drugs 20110122 |
| Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. | Behavioural brain research 20110120 |
| Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. | Molecular psychiatry 20110101 |
| Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs. | Biological research for nursing 20110101 |
| A thermodynamic-based approach to analyzing a highly solvating polymorphic system: the desolvation window method. | Journal of pharmaceutical sciences 20110101 |
| Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. | The Journal of clinical psychiatry 20110101 |
| Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. | Journal of obesity 20110101 |
| Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20110101 |
| Differential effects of ziprasidone and haloperidol on immobilization-stress-induced CRF mRNA expression in the hypothalamic paraventricular nucleus of rats. | Neuropsychobiology 20110101 |
| The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. | Expert review of neurotherapeutics 20110101 |
| Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110101 |
| One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. | BMC psychiatry 20110101 |
| Risperidone versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20110101 |
| Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. | Postgraduate medicine 20110101 |
| Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. | BMC psychiatry 20110101 |
| Weight gain, obesity, and psychotropic prescribing. | Journal of obesity 20110101 |
| Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). | Movement disorders : official journal of the Movement Disorder Society 20110101 |
| Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) or Hashimoto's encephalopathy: a case and review. | Psychosomatics 20110101 |
| Antipsychotics for the prevention and treatment of delirium in the intensive care unit: what is their role? | Harvard review of psychiatry 20110101 |
| Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? | Annals of general psychiatry 20110101 |
| Paliperidone extended-release: does it have a place in antipsychotic therapy? | Drug design, development and therapy 20110101 |
| Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. | Neuropsychiatric disease and treatment 20110101 |
| The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder. | Neuropsychiatric disease and treatment 20110101 |
| Pharmacotherapy for treatment-resistant schizophrenia. | Neuropsychiatric disease and treatment 20110101 |
| Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons? | Journal of translational medicine 20110101 |
| Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. | Cost effectiveness and resource allocation : C/E 20110101 |
| Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. | BMC psychiatry 20110101 |
| The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. | Neuropsychiatric disease and treatment 20110101 |
| Role of sublingual asenapine in treatment of schizophrenia. | Neuropsychiatric disease and treatment 20110101 |
| Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. | BMC psychiatry 20110101 |
| Clinical potential of lurasidone in the management of schizophrenia. | Therapeutics and clinical risk management 20110101 |
| Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. | Indian journal of psychiatry 20110101 |
| Predicting implementation from organizational readiness for change: a study protocol. | Implementation science : IS 20110101 |
| Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. | Patient preference and adherence 20110101 |
| Development and validation of an HPLC method for determination of ziprasidone and its impurities in pharmaceutical dosage forms. | Journal of AOAC International 20110101 |
| Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. | Depression research and treatment 20110101 |
| Acute hypersensitivity syndrome caused by valproic Acid: a review of the literature and a case report. | The Permanente journal 20110101 |
| A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. | PloS one 20110101 |
| Priapism due to a single dose of quetiapine: a case report. | Turk psikiyatri dergisi = Turkish journal of psychiatry 20110101 |
| Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. | BMC psychiatry 20110101 |
| A Data-Driven Investigation of Gray Matter-Function Correlations in Schizophrenia during a Working Memory Task. | Frontiers in human neuroscience 20110101 |
| Cytogenetic effects of valproic acid and ziprasidone in human lymphocyte cultures. | Neuropsychobiology 20110101 |
| Role of Beta-arrestin 2 downstream of dopamine receptors in the Basal Ganglia. | Frontiers in neuroanatomy 20110101 |
| Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder. | Journal of medical economics 20110101 |
| Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. | The primary care companion for CNS disorders 20110101 |
| Autism spectrum disorders and schizophrenia: meta-analysis of the neural correlates of social cognition. | PloS one 20110101 |
| Management of bipolar depression. | Indian journal of psychological medicine 20110101 |
| Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospital. | Indian journal of psychological medicine 20110101 |
| Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission. | Frontiers in molecular neuroscience 20110101 |
| Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study. | BMC psychiatry 20110101 |
| Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. | Frontiers in molecular neuroscience 20110101 |
| Clinical utility of the risperidone formulations in the management of schizophrenia. | Neuropsychiatric disease and treatment 20110101 |
| Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. | The Israel journal of psychiatry and related sciences 20110101 |
| Use of a new ziprasidone-selective electrode in mixed solvents and its application in the analysis of pharmaceuticals and biological fluids. | Sensors (Basel, Switzerland) 20110101 |
| Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses. | Neuro endocrinology letters 20110101 |
| Antidepressant drug exposure during pregnancy. CZTIS small prospective study. | Neuro endocrinology letters 20110101 |
| Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? | BMC psychiatry 20110101 |
| Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara. | BMC clinical pharmacology 20110101 |
| Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: a cross-sectional study. | Advances in urology 20110101 |
| Emergency anaesthetic management of a severely anaemic, chronic schizophrenic patient with history of neuroleptic malignant syndrome. | Indian journal of anaesthesia 20110101 |
| Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. | Patient preference and adherence 20110101 |
| Molecular-field-based three-dimensional similarity studies on quinoline-based CNS active agents. | ISRN pharmaceutics 20110101 |
| Practicing exorcism in schizophrenia. | BMJ case reports 20110101 |
| Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia. | Schizophrenia research and treatment 20110101 |
| An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. | Human psychopharmacology 20110101 |
| Compliance with atypical antipsychotic triage guidelines by Texas poison centers. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20101201 |
| Pediatric ziprasidone ingestions. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20101201 |
| Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20101201 |
| A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. | Expert opinion on drug metabolism & toxicology 20101201 |
| A case of catatonia successfully treated with ziprasidone, in a patient with DSM-IV delusional disorder. | Journal of clinical psychopharmacology 20101201 |
| Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. | Journal of clinical psychopharmacology 20101201 |
| Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability. | Current neuropharmacology 20101201 |
| Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse. | Neuroscience 20101124 |
| Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. | Schizophrenia research 20101101 |
| Mortality in schizophrenia: a measurable clinical endpoint. | Journal of psychopharmacology (Oxford, England) 20101101 |
| Cancer and schizophrenia: is there a paradox? | Journal of psychopharmacology (Oxford, England) 20101101 |
| Patients with schizophrenia show deficits of working memory maintenance components in circuit-specific tasks. | European archives of psychiatry and clinical neuroscience 20101001 |
| The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. | The Journal of clinical psychiatry 20101001 |
| Delusional infestation: neural correlates and antipsychotic therapy investigated by multimodal neuroimaging. | Progress in neuro-psychopharmacology & biological psychiatry 20101001 |
| Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. | Psychopharmacology 20101001 |
| Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. | Psychopharmacology 20101001 |
| Effects of atypical antipsychotics and haloperidol on PC12 cells: only aripiprazole phosphorylates AMP-activated protein kinase. | Journal of neural transmission (Vienna, Austria : 1996) 20101001 |
| Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. | Clinical schizophrenia & related psychoses 20101001 |
| Treatment with antipsychotics and the risk of diabetes in clinical practice. | The British journal of psychiatry : the journal of mental science 20101001 |
| Bitter pills for drug companies. | BMJ (Clinical research ed.) 20100917 |
| Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands. | Bioorganic & medicinal chemistry letters 20100915 |
| Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. | European journal of clinical pharmacology 20100901 |
| Strategies for successful clinical management of schizophrenia with ziprasidone. | Expert opinion on pharmacotherapy 20100901 |
| Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. | Pharmacotherapy 20100901 |
| Retrospective case series of aripiprazole augmentation in pervasive developmental disorders. | Psychiatry investigation 20100901 |
| Pharmacologic treatment of schizophrenia. | Dialogues in clinical neuroscience 20100901 |
| The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. | Clinics (Sao Paulo, Brazil) 20100901 |
| Antiepileptic drug interactions - principles and clinical implications. | Current neuropharmacology 20100901 |
| Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report. | Progress in neuro-psychopharmacology & biological psychiatry 20100816 |
| Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. | Progress in neuro-psychopharmacology & biological psychiatry 20100816 |
| Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. | Journal of evaluation in clinical practice 20100801 |
| A comparison of the chronic effects of human pharmaceuticals on two cladocerans, Daphnia magna and Ceriodaphnia dubia. | Chemosphere 20100801 |
| A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. | Journal of clinical psychopharmacology 20100801 |
| Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. | Pharmacopsychiatry 20100801 |
| Ziprasidone, monoamine oxidase inhibitors, and the serotonin syndrome. | Journal of clinical psychopharmacology 20100801 |
| Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial? | Journal of clinical psychopharmacology 20100801 |
| Iloperidone for the treatment of schizophrenia. | Drugs of today (Barcelona, Spain : 1998) 20100801 |
| Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database. | Current drug safety 20100702 |
| Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. | Schizophrenia research 20100701 |
| Atypical antipsychotic metabolism and excretion. | Current drug metabolism 20100701 |
| Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. | Expert review of neurotherapeutics 20100701 |
| Protracted, dose-dependent weight loss after addition of ziprasidone to a stable regimen of clozapine. | Human psychopharmacology 20100701 |
| Real-world Data on Atypical Antipsychotic Medication Side Effects. | Psychiatry (Edgmont (Pa. : Township)) 20100701 |
| Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes. | Talanta 20100630 |
| Ziprasidone-induced spontaneous orgasm. | Journal of psychopharmacology (Oxford, England) 20100601 |
| Synthesis, evaluation and computational studies on a series of acetophenone based 1-(aryloxypropyl)-4-(chloroaryl) piperazines as potential atypical antipsychotics. | European journal of medicinal chemistry 20100601 |
| Safety of the electroconvulsive therapy-ziprasidone combination. | The journal of ECT 20100601 |
| What do large scale studies of medication in schizophrenia add to our management strategies? | Psychiatria Danubina 20100601 |
| Predictive factors of social functioning in patients with schizophrenia: exploration for the best combination of variables using data mining. | Psychiatry investigation 20100601 |
| Serotonin syndrome caused by ziprasidone alone. | Psychiatry and clinical neurosciences 20100601 |
| Drug treatment of obsessive-compulsive disorder. | Dialogues in clinical neuroscience 20100601 |
| [Descriptive analysis of the use of atypical antipsychotics under compassionate-use in a health area in Ferrol (La Coruña, Spain)]. | Neurologia (Barcelona, Spain) 20100601 |
| Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100501 |
| Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. | Clinical neuropharmacology 20100501 |
| Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. | Evidence-based mental health 20100501 |
| Cortical motor neurophysiology of patients with schizophrenia: a study using transcranial magnetic stimulation. | Psychiatry research 20100430 |
| Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. | Journal of psychopharmacology (Oxford, England) 20100401 |
| Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. | Journal of affective disorders 20100401 |
| Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. | Current medical research and opinion 20100401 |
| Symptomatic bradycardia with oral aripiprazole and oral ziprasidone. | The Annals of pharmacotherapy 20100401 |
| Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. | Journal of clinical psychopharmacology 20100401 |
| A nearly overlooked mild case of ziprasidone-induced lingual dystonia. | Journal of clinical psychopharmacology 20100401 |
| Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. | Biochemical and biophysical research communications 20100305 |
| Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. | Schizophrenia bulletin 20100301 |
| Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro. | Journal of psychopharmacology (Oxford, England) 20100301 |
| Somatosensory system deficits in schizophrenia revealed by MEG during a median-nerve oddball task. | Brain topography 20100301 |
| The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100301 |
| Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? | Pharmacopsychiatry 20100301 |
| Pediatric uptake of a newly available antipsychotic medication. | Pediatrics 20100301 |
| Respiratory failure following isolated ziprasidone ingestion in a toddler. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20100301 |
| Ziprasidone as a possible cause of cleft palate in a newborn. | Psychiatria Danubina 20100301 |
| Systematic reviews of assessment measures and pharmacologic treatments for agitation. | Clinical therapeutics 20100301 |
| Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. | Clinical therapeutics 20100301 |
| Antipsychotics in pregnancy. | Journal of psychiatric and mental health nursing 20100301 |
| How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. | Journal of psychiatric practice 20100301 |
| Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. | Psychiatry research 20100227 |
| Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. | Schizophrenia research 20100201 |
| Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. | Journal of clinical psychopharmacology 20100201 |
| Torsade de pointes after ziprasidone overdose with coingestants. | Journal of clinical psychopharmacology 20100201 |
| Free your MIND and the rest will follow: decoding delirium in the intensive care unit. | Critical care medicine 20100201 |
| Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. | Critical care medicine 20100201 |
| Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. | Pharmacotherapy 20100201 |
| How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. | Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent 20100201 |
| Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. | The Journal of clinical psychiatry 20100201 |
| Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. | Psychiatric services (Washington, D.C.) 20100201 |
| Recommendations for pharmacological management of inpatient aggression in children and adolescents. | Psychiatry (Edgmont (Pa. : Township)) 20100201 |
| Zotepine versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20100120 |
| Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. | Journal of psychiatric research 20100101 |
| Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. | Pharmacology & therapeutics 20100101 |
| Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones in vitro. | British journal of pharmacology 20100101 |
| Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. | Archives of general psychiatry 20100101 |
| Amisulpride versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20100101 |
| Quetiapine versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20100101 |
| The successful treatment of mania due to acquired immunodeficiency syndrome using ziprasidone: a case series. | The Journal of neuropsychiatry and clinical neurosciences 20100101 |
| First-generation vs second-generation antipsychotic drugs: The ongoing saga. | Indian journal of psychiatry 20100101 |
| Beyond dopamine: functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis. | Frontiers in behavioral neuroscience 20100101 |
| QT alterations in psychopharmacology: proven candidates and suspects. | Current drug safety 20100101 |
| Olanzapine versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20100101 |
| Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. | BMC psychiatry 20100101 |
| Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. | Neuropsychiatric disease and treatment 20100101 |
| New atypical antipsychotics for schizophrenia: iloperidone. | Drug design, development and therapy 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. | Psychiatry (Edgmont (Pa. : Township)) 20100101 |
| A possible case of mixed mania due to neurosarcoidosis treated successfully with methylprednisolone and ziprasidone: another example of frontal-subcortical disinhibition? | General hospital psychiatry 20100101 |
| Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications. | The Journal of neuropsychiatry and clinical neurosciences 20100101 |
| The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. | BMC psychiatry 20100101 |
| Pharmacological interventions for borderline personality disorder. | The Cochrane database of systematic reviews 20100101 |
| Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade. | BMC research notes 20100101 |
| The impact of a standardised intramuscular sedation protocol for acute behavioural disturbance in the emergency department. | BMC emergency medicine 20100101 |
| Pharmacotherapy and the risk for community-acquired pneumonia. | BMC geriatrics 20100101 |
| S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance. | Cardiovascular psychiatry and neurology 20100101 |
| Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. | Patient preference and adherence 20100101 |
| Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. | BMC psychiatry 20100101 |
| Clearing up the confusion: the results of two pilot studies of antipsychotics for ICU delirium. | Critical care (London, England) 20100101 |
| Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia. | Indian journal of psychiatry 20100101 |
| Lithium, trifluperazine and idiopathic leucopenia: Author and reviewer perspectives on how to write a good case report. | Indian journal of psychiatry 20100101 |
| A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. | Annals of general psychiatry 20100101 |
| Emerging role of sertindole in the management of schizophrenia. | Neuropsychiatric disease and treatment 20100101 |
| Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. | Neuropsychiatric disease and treatment 20100101 |
| Emerging treatments in the management of schizophrenia - focus on sertindole. | Drug design, development and therapy 20100101 |
| Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia. | Frontiers in neuroscience 20100101 |
| Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence. | Patient preference and adherence 20100101 |
| Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. | Vascular health and risk management 20100101 |
| Hyperprolactinemia with antipsychotic drugs in children and adolescents. | International journal of pediatric endocrinology 20100101 |
| Database analysis of children and adolescents with bipolar disorder consuming a micronutrient formula. | BMC psychiatry 20100101 |
| Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database. | Journal of medical economics 20100101 |
| Predictors of switching antipsychotic medications in the treatment of schizophrenia. | BMC psychiatry 20100101 |
| Zotepine versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20100101 |
| Role of paliperidone extended-release in treatment of schizoaffective disorder. | Neuropsychiatric disease and treatment 20100101 |
| Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. | BMC psychiatry 20100101 |
| Patient perspectives on antipsychotic treatments and their association with clinical outcomes. | Patient preference and adherence 20100101 |
| Clozapine versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20100101 |
| New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature. | Case reports in medicine 20100101 |
| Angioneurotic edema with risperidone: a case report and review of literature. | General hospital psychiatry 20100101 |
| Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. | Neuropsychiatric disease and treatment 20100101 |
| Off-label second generation antipsychotics for impulse regulation disorders: a review. | Psychopharmacology bulletin 20100101 |
| Huntington's disease: a clinical review. | Orphanet journal of rare diseases 20100101 |
| Acute administration of clozapine and risperidone altered dopamine metabolism more in rat caudate than in nucleus accumbens: a dose-response relationship. | Scientia pharmaceutica 20100101 |
| Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. | PloS one 20100101 |
| Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management. | Mens sana monographs 20100101 |
| [Practical aspects of the use of ziprasidone in schizophrenia]. | Psychiatria polska 20100101 |
| Safety and tolerability of antipsychotics: focus on amisulpride. | Drug, healthcare and patient safety 20100101 |
| Notes from Underground: Are Cognitive-Enhancing Drugs Respecting their Promises? | Frontiers in psychology 20100101 |
| Stability of ziprasidone mesylate in an extemporaneously compounded oral solution. | The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20100101 |
| Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? | Psychiatry research 20091230 |
| Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. | Biological psychiatry 20091201 |
| Ziprasidone-related oculogyric crisis in an adult. | Clinical neurology and neurosurgery 20091201 |
| Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. | The Psychiatric quarterly 20091201 |
| Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). | Schizophrenia research 20091201 |
| Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors. | Bioorganic & medicinal chemistry letters 20091201 |
| Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. | Schizophrenia research 20091201 |
| Update on autism: a review of 1300 reports published in 2008. | Epilepsy & behavior : E&B 20091201 |
| Vocal tics associated with ziprasidone. | Journal of clinical psychopharmacology 20091201 |
| The comorbidity of diabetes mellitus and psychiatric disorders. | Psychiatria Danubina 20091201 |
| Brugada syndrome unmasked by lithium. | Southern medical journal 20091201 |
| Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder. | Journal of child and adolescent psychopharmacology 20091201 |
| The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. | Clinical therapeutics 20091201 |
| Comparative Analysis of Cognitive Function in Schizophrenia with and without Obsessive Compulsive Disorder. | Psychiatry investigation 20091201 |
| Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. | Current neuropharmacology 20091201 |
| Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. | Behavioural brain research 20091105 |
| Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. | Molecular psychiatry 20091101 |
| The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases. | Journal of psychopharmacology (Oxford, England) 20091101 |
| Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. | Schizophrenia research 20091101 |
| Ziprasidone monotherapy in bipolar II depression: an open trial. | Journal of affective disorders 20091101 |
| Asenapine effects in animal models of psychosis and cognitive function. | Psychopharmacology 20091101 |
| P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. | Pharmacological research 20091101 |
| The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. | Schizophrenia research 20091101 |
| Lurasidone: a new drug in development for schizophrenia. | Expert opinion on investigational drugs 20091101 |
| Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. | The American journal of psychiatry 20091101 |
| Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. | The international journal of neuropsychopharmacology 20091001 |
| Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. | Journal of child and adolescent psychopharmacology 20091001 |
| The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. | Pharmacoepidemiology and drug safety 20090901 |
| Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. | International clinical psychopharmacology 20090901 |
| Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone--a claims database approach. | Pharmacoepidemiology and drug safety 20090901 |
| Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. | Schizophrenia research 20090901 |
| What do we know about neuropsychological aspects of schizophrenia? | Neuropsychology review 20090901 |
| [Diabetes and second-generation (atypical) antipsychotics]. | Annales d'endocrinologie 20090901 |
| Pregnancy and atypical antipsychotics. | Psychiatria Danubina 20090901 |
| Activation induced by high-dose ziprasidone: a case report. | The Journal of clinical psychiatry 20090901 |
| Malignant catatonia in a patient with bipolar disorder, B12 deficiency, and neuroleptic malignant syndrome: one cause or three? | Journal of psychiatric practice 20090901 |
| The neurotrophic and neuroprotective effects of psychotropic agents. | Dialogues in clinical neuroscience 20090901 |
| Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. | CNS spectrums 20090901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090901 |
| FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. | JAMA 20090826 |
| Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. | Molecular psychiatry 20090801 |
| Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. | Schizophrenia research 20090801 |
| The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. | CNS drugs 20090801 |
| Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. | Schizophrenia research 20090801 |
| Using oral ziprasidone effectively: the food effect and dose-response. | Advances in therapy 20090801 |
| Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. | Journal of child and adolescent psychopharmacology 20090801 |
| [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090801 |
| Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. | Journal of medicinal chemistry 20090723 |
| Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia? | Schizophrenia bulletin 20090701 |
| In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. | Journal of psychiatric research 20090701 |
| Spatio-temporal clusters of new psychotropic medications among Michigan children insured by Medicaid. | Pharmacoepidemiology and drug safety 20090701 |
| Unintentional ingestion of ziprasidone in a 22-month-old. | Pediatric emergency care 20090701 |
| How dosing of ziprasidone in a state hospital system differs from product labeling. | The Journal of clinical psychiatry 20090701 |
| Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. | The Journal of clinical psychiatry 20090701 |
| Ziprasidone-induced angioedema: a case report. | The Journal of clinical psychiatry 20090701 |
| Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. | Diabetes care 20090601 |
| Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). | The American journal of psychiatry 20090601 |
| Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. | Schizophrenia research 20090601 |
| Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect. | Bioorganic & medicinal chemistry letters 20090601 |
| [Atypical antipsychotic efficacy and safety in managing delirium: a systematic review and critical analysis]. | Psychologie & neuropsychiatrie du vieillissement 20090601 |
| Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. | Journal of neurosurgery. Pediatrics 20090601 |
| Targeting cognition in schizophrenia research: from etiology to treatment. | The American journal of psychiatry 20090601 |
| A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. | The American journal of emergency medicine 20090601 |
| Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. | Journal of medical economics 20090601 |
| Antipsychotic agents in the treatment of bipolar mania. | Bipolar disorders 20090601 |
| In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner. | Journal of chemical biology 20090601 |
| Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. | The Journal of clinical psychiatry 20090601 |
| Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. | The Journal of clinical psychiatry 20090601 |
| Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. | Clinical therapeutics 20090601 |
| Models of aspects of schizophrenia: behavioral sensitization induced by subchronic phencyclidine administration. | Current protocols in pharmacology 20090601 |
| Atypical antipsychotic drugs and the risk of sudden cardiac death. | The New England journal of medicine 20090514 |
| Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. | Journal of psychopharmacology (Oxford, England) 20090501 |
| Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. | Schizophrenia research 20090501 |
| Weight effects associated with antipsychotics: a comprehensive database analysis. | Schizophrenia research 20090501 |
| Akathisia and second-generation antipsychotic drugs. | Current opinion in psychiatry 20090501 |
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. | Bipolar disorders 20090501 |
| Use and safety of antipsychotic drugs during pregnancy. | Journal of psychiatric practice 20090501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090501 |
| Switch to ziprazidone treatment is associated with changes in MMN amplitude: a case report. | Progress in neuro-psychopharmacology & biological psychiatry 20090430 |
| Akathisia: an updated review focusing on second-generation antipsychotics. | The Journal of clinical psychiatry 20090421 |
| Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. | The Journal of clinical psychiatry 20090421 |
| 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay. | European journal of pharmacology 20090417 |
| Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies. | Psychopharmacology 20090401 |
| The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. | European psychiatry : the journal of the Association of European Psychiatrists 20090401 |
| Low concentration of ziprasidone in human milk: a case report. | The international journal of neuropsychopharmacology 20090401 |
| Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. | European journal of pharmacology 20090401 |
| Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. | Human psychopharmacology 20090401 |
| How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. | European psychiatry : the journal of the Association of European Psychiatrists 20090401 |
| Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study. | The Journal of clinical psychiatry 20090401 |
| Pediatric ziprasidone overdose. | Pediatric emergency care 20090401 |
| Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. | Clinical therapeutics 20090401 |
| Development and validation of a high throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of diltiazem and its two metabolites in human plasma: Application to a bioequivalence study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090315 |
| Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. | Schizophrenia research 20090301 |
| Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. | Schizophrenia research 20090301 |
| Evaluation of Peakmaster for computer-aided multivariate optimisation of a CE separation of 17 antipsychotic drugs using minimal experimental data. | Electrophoresis 20090301 |
| Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20090301 |
| A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. | Community mental health journal 20090201 |
| A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. | The American journal of psychiatry 20090201 |
| Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone. | Progress in neuro-psychopharmacology & biological psychiatry 20090201 |
| Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. | Journal of clinical psychopharmacology 20090201 |
| Metabolic risks in older adults receiving second-generation antipsychotic medication. | Current psychiatry reports 20090201 |
| Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. | Lancet (London, England) 20090103 |
| Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. | Journal of psychopharmacology (Oxford, England) 20090101 |
| Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. | Journal of psychiatric research 20090101 |
| A placebo-controlled study of sildenafil effects on cognition in schizophrenia. | Psychopharmacology 20090101 |
| Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20090101 |
| The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. | The Journal of clinical psychiatry 20090101 |
| Results of phase 3 of the CATIE schizophrenia trial. | Schizophrenia research 20090101 |
| Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. | Research in developmental disabilities 20090101 |
| Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? | Current drug safety 20090101 |
| Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. | Pharmacopsychiatry 20090101 |
| A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20090101 |
| Extrapyramidal side effects: could you identify them in the emergency department? | Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association 20090101 |
| Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. | Psychopharmacology bulletin 20090101 |
| Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. | Annals of general psychiatry 20090101 |
| Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. | Nutrition & metabolism 20090101 |
| Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice. | Frontiers in behavioral neuroscience 20090101 |
| New therapeutic approach to Tourette Syndrome in children based on a randomized placebo-controlled double-blind phase IV study of the effectiveness and safety of magnesium and vitamin B6. | Trials 20090101 |
| Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. | Child and adolescent psychiatry and mental health 20090101 |
| Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. | BMC psychiatry 20090101 |
| Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. | BMC psychiatry 20090101 |
| Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. | Cost effectiveness and resource allocation : C/E 20090101 |
| Sertindole versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20090101 |
| Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. | Trials 20090101 |
| Schizophrenia pathophysiology: are we any closer to a complete model? | Annals of general psychiatry 20090101 |
| Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. | CNS drugs 20090101 |
| Persistence and compliance to antidepressant treatment in patients with depression: a chart review. | BMC psychiatry 20090101 |
| Update on the management of symptoms in schizophrenia: focus on amisulpride. | Neuropsychiatric disease and treatment 20090101 |
| Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole. | Neuropsychiatric disease and treatment 20090101 |
| Comparison of the efficacy of two anticonvulsants, phenytoin and valproate to improve PCP and d-amphetamine induced deficits in a reversal learning task in the rat. | Frontiers in behavioral neuroscience 20090101 |
| [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy]. | Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 20090101 |
| Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. | The Cochrane database of systematic reviews 20090101 |
| Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. | BMC psychiatry 20090101 |
| Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. | Annals of general psychiatry 20090101 |
| Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. | BMC psychiatry 20090101 |
| The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. | Clinical neuropharmacology 20090101 |
| Tardive dyskinesia in a patient treated with quetiapine. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20090101 |
| Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study. | Neuro endocrinology letters 20090101 |
| A failed case of weaning from a mechanical ventilator with lorazepam successfully accomplished by ziprasidone. | General hospital psychiatry 20090101 |
| Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone). | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. | BMC psychiatry 20090101 |
| Mean and variability of QT-interval: Relevance to psychiatric illness and psychotropic medication. | Indian journal of psychiatry 20090101 |
| More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation. | Indian journal of psychiatry 20090101 |
| Switching to duloxetine remits ziprasidone - associated urinary incontinence and improves neuropsychiatric behavior in dementia: possible relationship of incontinence to 5HT2 receptor blockade. | Psychopharmacology bulletin 20090101 |
| Aripiprazole versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20090101 |
| Ziprasidone versus other atypical antipsychotics for schizophrenia. | The Cochrane database of systematic reviews 20090101 |
| CATIE and CUtLASS (UK): Is it time psychiatrists start changing their practice?- The debate goes on! | Indian journal of psychiatry 20090101 |
| Development of Parkinsonism following exposure to aripiprazole: two case reports. | Journal of medical case reports 20090101 |
| Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia. | Neuropsychiatric disease and treatment 20090101 |
| Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients. | Indian journal of psychiatry 20090101 |
| Algorithms for the assessment and management of insomnia in primary care. | Patient preference and adherence 20090101 |
| Evidence for anomalous network connectivity during working memory encoding in schizophrenia: an ICA based analysis. | PloS one 20090101 |
| New-onset vascular mania in a patient with chronic depression. | The Journal of neuropsychiatry and clinical neurosciences 20090101 |
| Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. | Annals of general psychiatry 20090101 |
| Current perspectives in the treatment of resistant schizophrenia. | Indian journal of psychiatry 20090101 |
| The story of antipsychotics: Past and present. | Indian journal of psychiatry 20090101 |
| Increased sexual aggression following ziprasidone discontinuation in an intellectually disabled adult man. | Primary care companion to the Journal of clinical psychiatry 20090101 |
| Ziprasidone induced tardive cervical dystonia. | Psychopharmacology bulletin 20090101 |
| Behavioral and psychological symptoms of dementia and their management. | Indian journal of psychiatry 20090101 |
| Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? | Behavioural brain research 20081216 |
| Neurological adverse events associated with antipsychotic treatment in children and adolescents. | Journal of child neurology 20081201 |
| Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. | Therapeutic drug monitoring 20081201 |
| [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics]. | Fortschritte der Neurologie-Psychiatrie 20081201 |
| One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. | Current medical research and opinion 20081201 |
| Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). | Journal of clinical psychopharmacology 20081201 |
| Ziprasidone-associated mania in Korean schizophrenic patient. | Journal of clinical psychopharmacology 20081201 |
| A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. | The Journal of clinical psychiatry 20081201 |
| Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. | Neuropsychiatric disease and treatment 20081201 |
| New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. | Neuropsychiatric disease and treatment 20081201 |
| The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. | Bipolar disorders 20081201 |
| Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. | European journal of pharmacology 20081112 |
| Focus on ziprasidone: a review of its use in child and adolescent psychiatry. | Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent 20081101 |
| A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. | Schizophrenia research 20081001 |
| Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. | Therapeutic drug monitoring 20081001 |
| Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. | Schizophrenia research 20081001 |
| Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. | Journal of clinical psychopharmacology 20081001 |
| Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. | Genetics in medicine : official journal of the American College of Medical Genetics 20081001 |
| Extrapyramidal side-effects of antipsychotics in a randomised trial. | The British journal of psychiatry : the journal of mental science 20081001 |
| Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. | Psychiatric services (Washington, D.C.) 20081001 |
| Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. | Journal of child and adolescent psychopharmacology 20081001 |
| Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. | Psychiatry and clinical neurosciences 20081001 |
| Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. | CNS spectrums 20081001 |
| Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. | The American journal of geriatric pharmacotherapy 20081001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| Augmentation treatment in major depressive disorder: focus on aripiprazole. | Neuropsychiatric disease and treatment 20081001 |
| Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. | The Journal of clinical psychiatry 20081001 |
| Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. | Brain research bulletin 20080930 |
| The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. | European journal of pharmacology 20080911 |
| A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice. | Behavioural pharmacology 20080901 |
| Role of the central cholinergic system in the therapeutics of schizophrenia. | Current neuropharmacology 20080901 |
| Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. | Behavioural brain research 20080805 |
| Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. | Schizophrenia research 20080801 |
| Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. | Bioorganic & medicinal chemistry 20080801 |
| Repeated acute dystonia following administration of amisulpride and ziprasidone in a patient with iron deficiency. | Progress in neuro-psychopharmacology & biological psychiatry 20080801 |
| QTc Prolongation Associated with Ziprasidone Overdose. | CNS spectrums 20080801 |
| Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. | Journal of Korean medical science 20080801 |
| Current approaches to the treatment of Parkinson's disease. | Neuropsychiatric disease and treatment 20080801 |
| Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. | Therapeutics and clinical risk management 20080801 |
| Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. | Progress in neuro-psychopharmacology & biological psychiatry 20080701 |
| Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. | Journal of psychopharmacology (Oxford, England) 20080701 |
| Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry. | Biomedical chromatography : BMC 20080701 |
| Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. | Schizophrenia research 20080701 |
| Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. | Acta psychiatrica Scandinavica 20080701 |
| Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. | Psychopharmacology 20080701 |
| Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. | International clinical psychopharmacology 20080701 |
| Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. | The Journal of clinical psychiatry 20080701 |
| Profound hypothermia secondary to normal ziprasidone use. | The American journal of emergency medicine 20080701 |
| Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080601 |
| Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. | Neuropharmacology 20080601 |
| Inadvertent administration of intravenous ziprasidone leading to bradycardia and QT interval prolongation. | The Annals of pharmacotherapy 20080601 |
| First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. | The British journal of psychiatry : the journal of mental science 20080601 |
| Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. | Current drug metabolism 20080601 |
| Clinical experiences and clinical trials. | CNS spectrums 20080601 |
| Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. | Clinical interventions in aging 20080601 |
| Acute and long-term treatment of mania. | Dialogues in clinical neuroscience 20080601 |
| Current research in child and adolescent bipolar disorder. | Dialogues in clinical neuroscience 20080601 |
| Administration of ziprasidone for 10 days increases cocaine toxicity in mice. | Human & experimental toxicology 20080601 |
| Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). | Current neuropharmacology 20080601 |
| Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080501 |
| Did CATIE influence antipsychotic use? | Psychiatric services (Washington, D.C.) 20080501 |
| What CATIE found: results from the schizophrenia trial. | Psychiatric services (Washington, D.C.) 20080501 |
| Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080401 |
| Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. | Acta psychiatrica Scandinavica 20080401 |
| Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. | The journal of behavioral health services & research 20080401 |
| Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. | The Journal of clinical psychiatry 20080401 |
| Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. | Schizophrenia research 20080401 |
| Ziprasidone-induced hyperprolactinemia: a case report. | Progress in neuro-psychopharmacology & biological psychiatry 20080401 |
| Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. | Journal of clinical psychopharmacology 20080401 |
| Sexual dysfunction in schizophrenia: focus on recent evidence. | Human psychopharmacology 20080401 |
| Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. | Journal of clinical psychopharmacology 20080401 |
| High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. | Journal of clinical psychopharmacology 20080401 |
| [Ziprasidone in Parkinsonian dopamine psychosis]. | Revista de neurologia 20080401 |
| Problems with CATIE. Phase 1: Looking back--what the clinician needs to know. | Connecticut medicine 20080401 |
| [Atypical antipsychotics in first-episode psychosis: a review]. | L'Encephale 20080401 |
| Pattern of ziprasidone exposures reported to Texas poison centers, 2001-2005. | Human & experimental toxicology 20080401 |
| Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients. | Neuropsychiatric disease and treatment 20080401 |
| Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. | Lancet (London, England) 20080329 |
| Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. | Behavioural brain research 20080305 |
| [Recurrent dysregulation of body temperature during antipsychotic pharmacotherapy]. | Psychiatrische Praxis 20080301 |
| The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. | Schizophrenia research 20080301 |
| Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. | Current medical research and opinion 20080301 |
| Paliperidone for schizophrenia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301 |
| Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301 |
| Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. | Journal of psychopharmacology (Oxford, England) 20080301 |
| Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. | Behavioural pharmacology 20080301 |
| Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS. | Journal of analytical toxicology 20080301 |
| Urinary retention associated with ziprasidone: a case report. | The Journal of clinical psychiatry 20080301 |
| Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. | European journal of pharmacology 20080226 |
| Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease. | Progress in neuro-psychopharmacology & biological psychiatry 20080215 |
| Determination of Ziprasidone in pharmaceutical formulations by capillary zone electrophoresis. | Journal of pharmaceutical and biomedical analysis 20080213 |
| A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. | The Journal of clinical psychiatry 20080201 |
| Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings. | Neuropsychiatric disease and treatment 20080201 |
| Quetiapine monotherapy for bipolar depression. | Neuropsychiatric disease and treatment 20080201 |
| Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. | Neuropsychiatric disease and treatment 20080201 |
| 1-Aminoindanes as novel motif with potential atypical antipsychotic properties. | Bioorganic & medicinal chemistry letters 20080115 |
| Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. | Biological psychiatry 20080101 |
| Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. | Schizophrenia research 20080101 |
| The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. | Progress in neuro-psychopharmacology & biological psychiatry 20080101 |
| Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. | Molecular psychiatry 20080101 |
| Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. | Schizophrenia bulletin 20080101 |
| Evaluating dose response from flexible dose clinical trials. | BMC psychiatry 20080101 |
| Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. | European psychiatry : the journal of the Association of European Psychiatrists 20080101 |
| Use of antipsychotics to treat cocaine toxicity? | Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20080101 |
| Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. | Journal of psychiatric practice 20080101 |
| Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20080101 |
| Acute pisa syndrome and pharnygolaryngeal dystonia due to ziprasidone. | The Journal of neuropsychiatry and clinical neurosciences 20080101 |
| Tardive dystonia and ziprasidone: a case report. | Primary care companion to the Journal of clinical psychiatry 20080101 |
| The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. | The Journal of clinical psychiatry 20080101 |
| Incorporating clinical guidelines through clinician decision-making. | Implementation science : IS 20080101 |
| The use of atypical antipsychotics after traumatic brain injury. | The Journal of head trauma rehabilitation 20080101 |
| Cost of antipsychotic polypharmacy in the treatment of schizophrenia. | BMC psychiatry 20080101 |
| Critical thinking about adverse drug effects: lessons from the psychology of risk and medical decision-making for clinical psychopharmacology. | Psychotherapy and psychosomatics 20080101 |
| Ziprasidone-induced tardive laryngeal dystonia: a case report. | General hospital psychiatry 20080101 |
| Effectiveness of second generation antipsychotics: a systematic review of randomized trials. | BMC psychiatry 20080101 |
| Pharmacological management of atypical antipsychotic-induced weight gain. | CNS drugs 20080101 |
| Delirium in the intensive care unit. | Critical care (London, England) 20080101 |
| The use of atypical antipsychotics in pediatric bipolar disorder. | The Journal of clinical psychiatry 20080101 |
| Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. | The Journal of clinical psychiatry 20080101 |
| Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. | The Journal of clinical psychiatry 20080101 |
| Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. | Clinical drug investigation 20080101 |
| Commentary on strategies for switching antipsychotics. | BMC medicine 20080101 |
| Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. | Journal of the American Pharmacists Association : JAPhA 20080101 |
| Case report of oculogyric crisis with ziprasidone in a minor. | Primary care companion to the Journal of clinical psychiatry 20080101 |
| Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial. | BMC psychiatry 20080101 |
| Pathophysiology and treatment of psychosis in Parkinson's disease: a review. | Drugs & aging 20080101 |
| [Brain in the core of metabolic regulations: disorders in schizophrenic patients treated with atypical antipsychotics]. | Revue medicale de Liege 20080101 |
| Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. | Clinical neuropharmacology 20080101 |
| Association between antipsychotics and weight gain among psychiatric outpatients in Pakistan: a retrospective cohort study. | Annals of general psychiatry 20080101 |
| Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. | Annals of general psychiatry 20080101 |
| Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. | Progress in brain research 20080101 |
| Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. | PloS one 20080101 |
| [Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20080101 |
| Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007. | Primary care companion to the Journal of clinical psychiatry 20080101 |
| Lithium intoxication related multiple temporary ecg changes: A case report. | Cases journal 20080101 |
| Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics. | CNS drugs 20080101 |
| Gateways to clinical trials. July-August 2008. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia. | Frontiers in molecular neuroscience 20080101 |
| A case of PTSD presenting with psychotic symptomatology: a case report. | Cases journal 20080101 |
| Intraocular pressure in schizophrenic patients treated with psychiatric medications. | Arquivos brasileiros de oftalmologia 20080101 |
| Ziprasidone in the treatment of affective disorders: a review. | CNS neuroscience & therapeutics 20080101 |
| The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | BMC psychiatry 20080101 |
| A possible case of Capgras syndrome after a right anterior cerebral artery cerebrovascular accident treated successfully with mirtazapine. | The Journal of neuropsychiatry and clinical neurosciences 20080101 |
| [Potentially lethal cardiac side effects caused by psychiatric drugs]. | Vertex (Buenos Aires, Argentina) 20080101 |
| Are we over-dependent on pharmacotherapy? | Indian journal of psychiatry 20080101 |
| Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. | Patient preference and adherence 20080101 |
| Psychosis following anti-obesity treatment with rimonabant. | Obesity facts 20080101 |
| Hereditary multiple exostoses and schizophrenia. | Indian journal of human genetics 20080101 |
| Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20071201 |
| Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists. | Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 20071201 |
| Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. | Journal of clinical psychopharmacology 20071201 |
| QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20071201 |
| A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. | Bipolar disorders 20071201 |
| Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. | The Journal of clinical psychiatry 20071201 |
| Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. | The Journal of clinical psychiatry 20071201 |
| Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. | Clinical toxicology (Philadelphia, Pa.) 20071201 |
| Management of the behavioral and psychological symptoms of dementia. | Clinical interventions in aging 20071201 |
| Ziprasidone in adolescents with autism: an open-label pilot study. | Journal of child and adolescent psychopharmacology 20071201 |
| Ziprasidone in the treatment of mania in bipolar disorder. | Neuropsychiatric disease and treatment 20071201 |
| Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review. | Neuropsychiatric disease and treatment 20071201 |
| Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. | Neuropsychiatric disease and treatment 20071201 |
| A review of quetiapine in combination with antidepressant therapy in patients with depression. | Neuropsychiatric disease and treatment 20071201 |
| Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. | Neuropsychiatric disease and treatment 20071201 |
| Current therapeutic options for Alzheimer's disease. | Current genomics 20071201 |
| Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. | Current medical research and opinion 20071101 |
| Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. | International clinical psychopharmacology 20071101 |
| The many faces of psychosis in the elderly. | Current opinion in psychiatry 20071101 |
| Clinical relevance of relative receptor binding affinity: quetiapine and ziprasidone as examples. | Journal of psychiatric practice 20071101 |
| Treatment of bipolar disorder: the evolving role of atypical antipsychotics. | The American journal of managed care 20071101 |
| Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. | The Journal of clinical psychiatry 20071101 |
| Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. | Journal of medicinal chemistry 20071018 |
| Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071015 |
| The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. | Psychopharmacology 20071001 |
| The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features. | Progress in neuro-psychopharmacology & biological psychiatry 20071001 |
| The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care. | Progress in neuro-psychopharmacology & biological psychiatry 20071001 |
| Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. | Progress in neuro-psychopharmacology & biological psychiatry 20071001 |
| Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. | Current medical research and opinion 20071001 |
| Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats. | British journal of pharmacology 20071001 |
| Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. | Naunyn-Schmiedeberg's archives of pharmacology 20071001 |
| Acute urinary retention associated with selective serotonin reuptake inhibitors and ziprasidone. | Journal of clinical psychopharmacology 20071001 |
| Managing the acutely agitated and psychotic patient. | CNS spectrums 20071001 |
| Practical strategies for assessing and stabilizing bipolar patients in urgent situations. | The Journal of clinical psychiatry 20071001 |
| Pharmacological causes of hyperprolactinemia. | Therapeutics and clinical risk management 20071001 |
| Review of olanzapine in the management of bipolar disorders. | Neuropsychiatric disease and treatment 20071001 |
| Complex obsessive compulsive and impulsive symptoms in Tourette's syndrome. | Neuropsychiatric disease and treatment 20071001 |
| Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. | Psychiatry (Edgmont (Pa. : Township)) 20071001 |
| Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901 |
| Risperidone- and quetiapine-induced cholestasis. | The Annals of pharmacotherapy 20070901 |
| Show me the evidence: using number needed to treat. | Southern medical journal 20070901 |
| Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. | The Journal of clinical psychiatry 20070901 |
| Olanzapine and acute urinary retention in two geriatric patients. | The American journal of geriatric pharmacotherapy 20070901 |
| Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. | Journal of psychiatric research 20070801 |
| In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. | Journal of psychopharmacology (Oxford, England) 20070801 |
| The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. | Schizophrenia research 20070801 |
| Impairment in error monitoring predicts poor executive function in schizophrenia patients. | Schizophrenia research 20070801 |
| Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. | Human psychopharmacology 20070801 |
| Ziprasidone, diazepam, or the combination for prevention of cocaine toxicity in a mouse model. | Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20070801 |
| Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. | Evidence-based mental health 20070801 |
| N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. | Current drug metabolism 20070801 |
| Metabolic effects of the atypical antipsychotics. | Southern medical journal 20070801 |
| A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed. | Journal of child and adolescent psychopharmacology 20070801 |
| Ziprasidone-associated mania in a case of obssessive-compulsive disorder. | CNS spectrums 20070801 |
| Effectiveness of olanzapine in neurosyphilis related organic psychosis: a case report. | Journal of psychopharmacology (Oxford, England) 20070701 |
| Possible case of allopurinol causing relapse of psychosis. | Schizophrenia research 20070701 |
| Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. | Psychopharmacology 20070701 |
| Urticaria and angio-oedema due to ziprasidone. | Journal of psychopharmacology (Oxford, England) 20070701 |
| Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. | Current opinion in investigational drugs (London, England : 2000) 20070701 |
| Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. | The Journal of clinical psychiatry 20070701 |
| Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. | Molecular psychiatry 20070601 |
| Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. | Bone marrow transplantation 20070601 |
| All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. | Journal of clinical psychopharmacology 20070601 |
| Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | Archives of general psychiatry 20070601 |
| Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. | The Journal of clinical psychiatry 20070601 |
| A different mechanism to understand activation/sedation side effects of ziprasidone. | The Journal of clinical psychiatry 20070601 |
| Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches. | Dialogues in clinical neuroscience 20070601 |
| Quality of life in schizophrenic patients. | Dialogues in clinical neuroscience 20070601 |
| Ziprasidone-induced acute laryngeal dystonia. | Progress in neuro-psychopharmacology & biological psychiatry 20070509 |
| Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. | Progress in neuro-psychopharmacology & biological psychiatry 20070509 |
| A clinical study of the association of antipsychotics with hyperlipidemia. | Schizophrenia research 20070501 |
| Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. | Bipolar disorders 20070501 |
| Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. | Pharmacopsychiatry 20070501 |
| Antipsychotics for delirium. | The Cochrane database of systematic reviews 20070418 |
| Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. | European psychiatry : the journal of the Association of European Psychiatrists 20070401 |
| The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. | European archives of psychiatry and clinical neuroscience 20070401 |
| Use of atypical antipsychotics in the treatment of autistic disorder. | The Annals of pharmacotherapy 20070401 |
| Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. | Archives of general psychiatry 20070401 |
| Atypical antipsychotic drug-induced acute laryngeal dystonia: 2 case reports. | Journal of clinical psychopharmacology 20070401 |
| Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. | The Journal of clinical psychiatry 20070401 |
| Ziprasidone-associated galactorrhea in an adolescent female. | Journal of child and adolescent psychopharmacology 20070401 |
| Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. | Journal of child and adolescent psychopharmacology 20070401 |
| Quetiapine in the treatment of schizophrenia and related disorders. | Neuropsychiatric disease and treatment 20070401 |
| An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration. | Neuropsychiatric disease and treatment 20070401 |
| Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. | Progress in neuro-psychopharmacology & biological psychiatry 20070330 |
| High-dose ziprasidone-induced acute dystonia. | Progress in neuro-psychopharmacology & biological psychiatry 20070330 |
| Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. | Progress in neuro-psychopharmacology & biological psychiatry 20070330 |
| Use of ziprasidone in patients with fibromyalgia: a case series. | Rheumatology international 20070301 |
| Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. | European child & adolescent psychiatry 20070301 |
| Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070301 |
| Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. | Neuropharmacology 20070301 |
| Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. | The American journal of psychiatry 20070301 |
| Management of agitation in the acute psychotic patient--efficacy without excessive sedation. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20070301 |
| The stable patient with schizophrenia--from antipsychotic effectiveness to adherence. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20070301 |
| 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. | Brain research 20070223 |
| [Psychotropic drug-induced change of weight: a review]. | Fortschritte der Neurologie-Psychiatrie 20070201 |
| Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. | The international journal of neuropsychopharmacology 20070201 |
| Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. | Clinical neurology and neurosurgery 20070201 |
| Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070201 |
| [Cenesthesia as a rare differential diagnosis of persistent idiopathic facial pain]. | Der Nervenarzt 20070201 |
| Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. | Journal of clinical psychopharmacology 20070201 |
| Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. | Psychopharmacology 20070201 |
| Quality of life in the long-term treatment and the role of second-generation antipsychotics. | Neuro endocrinology letters 20070201 |
| Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics. | The Annals of pharmacotherapy 20070201 |
| Multi-drug overdose risperidone, ziprasidone, valproate, trihexyphenidyl, and clonazepam. | The Journal of the Association of Physicians of India 20070201 |
| Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. | Neuropsychiatric disease and treatment 20070201 |
| Does antipsychotic polypharmacy increase the risk for metabolic syndrome? | Schizophrenia research 20070101 |
| Atypical antipsychotics in the treatment of mood disorders. | Current opinion in psychiatry 20070101 |
| Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. | Pharmacotherapy 20070101 |
| Metabolic drug interactions with newer antipsychotics: a comparative review. | Basic & clinical pharmacology & toxicology 20070101 |
| Datapoints: The ups and downs of dosing second-generation antipsychotics. | Psychiatric services (Washington, D.C.) 20070101 |
| A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20070101 |
| Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. | Annals of general psychiatry 20070101 |
| Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. | Clinical neuropharmacology 20070101 |
| Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. | Psychopharmacology bulletin 20070101 |
| Treatment refractory psychosis remitted upon treatment with continuous positive airway pressure: a case report. | Psychopharmacology bulletin 20070101 |
| The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. | The Journal of clinical psychiatry 20070101 |
| Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. | The Journal of clinical psychiatry 20070101 |
| Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. | Rapid communications in mass spectrometry : RCM 20070101 |
| Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia. | Behavioural neurology 20070101 |
| Medical post-traumatic stress disorder: catching up with the cutting edge in stress research. | Critical care (London, England) 20070101 |
| Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20070101 |
| 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes. | Clinical and experimental pharmacology & physiology 20070101 |
| Comments on the report of neuroleptic malignant syndrome induced by ziprasidone. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20070101 |
| Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. | Clinical pharmacokinetics 20070101 |
| QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. | Annals of general psychiatry 20070101 |
| Cocaine use as a risk factor for ziprasidone-induced acute dystonia. | General hospital psychiatry 20070101 |
| Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. | Journal of the American Pharmacists Association : JAPhA 20070101 |
| Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. | BMC psychiatry 20070101 |
| Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). | Actas espanolas de psiquiatria 20070101 |
| Stem cell therapy for autism. | Journal of translational medicine 20070101 |
| Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20070101 |
| Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. | CNS drug reviews 20070101 |
| [Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics]. | L'Encephale 20070101 |
| Adjunctive treatment of acute mania: a clinical overview. | Acta psychiatrica Scandinavica. Supplementum 20070101 |
| Bipolar II disorder : epidemiology, diagnosis and management. | CNS drugs 20070101 |
| Atypical antipsychotics in children with pervasive developmental disorders. | Paediatric drugs 20070101 |
| Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial. | Clinical drug investigation 20070101 |
| Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. | BMC psychiatry 20070101 |
| Ziprasidone security in overdose: one case report. | Actas espanolas de psiquiatria 20070101 |
| Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. | CNS drugs 20070101 |
| [Charles-Bonnet Syndrome: a report of two cases]. | Turk psikiyatri dergisi = Turkish journal of psychiatry 20070101 |
| Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report. | Annals of general psychiatry 20070101 |
| The CATIE schizophrenia trial: results, impact, controversy. | Harvard review of psychiatry 20070101 |
| Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. | Annals of general psychiatry 20070101 |
| Prospective observational multi-poison center study of ziprasidone exposures. | Clinical toxicology (Philadelphia, Pa.) 20070101 |
| Adverse effects of atypical antipsychotics : differential risk and clinical implications. | CNS drugs 20070101 |
| The effect of food on the absorption of oral ziprasidone. | Psychopharmacology bulletin 20070101 |
| Perception versus polysomnographic assessment of sleep in CFS and non-fatigued control subjects: results from a population-based study. | BMC neurology 20070101 |
| A case report with ziprasidone-induced catatonic symptoms. | The Journal of neuropsychiatry and clinical neurosciences 20070101 |
| Ziprasidone-associated depressive state in schizophrenic patients. | Clinical neuropharmacology 20070101 |
| Monocytosis subsequent to ziprasidone treatment: a possible side effect. | Primary care companion to the Journal of clinical psychiatry 20070101 |
| Ziprasidone-induced tardive dyskinesia in a patient without known risk factors. | The National medical journal of India 20070101 |
| Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. | Patient preference and adherence 20070101 |
| Rejoinder in reply to critical appraisal on 'factitious schizophrenia'. | Indian journal of psychiatry 20070101 |
| Paliperidone: the evidence of its therapeutic value in schizophrenia. | Core evidence 20070101 |
| Pancreatitis following Olanzapine Therapy: A Report of Three Cases. | Case reports in gastroenterology 20070101 |
| A patient using ziprasidone with polydipsia, seizure, hyponatremia and rhabdomyolysis. | Progress in neuro-psychopharmacology & biological psychiatry 20061230 |
| Ziprasidone in the treatment of Parkinson's disease psychosis. | European psychiatry : the journal of the Association of European Psychiatrists 20061201 |
| Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. | The international journal of neuropsychopharmacology 20061201 |
| A model of anticholinergic activity of atypical antipsychotic medications. | Schizophrenia research 20061201 |
| Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. | Schizophrenia research 20061201 |
| Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. | Synapse (New York, N.Y.) 20061201 |
| Acute treatment of mania: an update on new medications. | Current psychiatry reports 20061201 |
| Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. | Journal of clinical psychopharmacology 20061201 |
| Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. | The American journal of psychiatry 20061201 |
| Treatment of psychosis: 30 years of progress. | Journal of clinical pharmacy and therapeutics 20061201 |
| A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. | Journal of child and adolescent psychopharmacology 20061201 |
| [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20061201 |
| Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. | Current medical research and opinion 20061201 |
| Treatments for late-life bipolar disorder. | The American journal of geriatric pharmacotherapy 20061201 |
| Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. | Neuropsychiatric disease and treatment 20061201 |
| Cognitive deficits and functional outcome in schizophrenia. | Neuropsychiatric disease and treatment 20061201 |
| Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. | Psychiatry research 20061115 |
| Early changes of plasma lipids during treatment with atypical antipsychotics. | International clinical psychopharmacology 20061101 |
| New treatments for tic disorders. | Current treatment options in neurology 20061101 |
| Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. | The Annals of pharmacotherapy 20061101 |
| Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone. | Evidence-based mental health 20061101 |
| Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. | International journal of clinical practice 20061101 |
| Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. | The British journal of psychiatry : the journal of mental science 20061101 |
| Acute dystonic reaction in an adolescent with low-dose of ziprasidone. | Psychiatry (Edgmont (Pa. : Township)) 20061101 |
| Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease. | Psychiatry (Edgmont (Pa. : Township)) 20061101 |
| Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061020 |
| Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. | Life sciences 20061004 |
| Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? | Schizophrenia research 20061001 |
| Sex selection bias in schizophrenia antipsychotic trials. | Journal of clinical psychopharmacology 20061001 |
| The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. | The Journal of emergency medicine 20061001 |
| Hyperlipidemia following treatment with antipsychotic medications. | The American journal of psychiatry 20061001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061001 |
| Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060901 |
| Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060901 |
| Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060901 |
| SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? | Molecular and cellular biochemistry 20060901 |
| A model for antipsychotic-induced obesity in the male rat. | Psychopharmacology 20060901 |
| Differential metabolic effects of antipsychotic treatments. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20060901 |
| A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. | The European journal of health economics : HEPAC : health economics in prevention and care 20060901 |
| Probable association between ziprasidone and worsening hypertension. | Pharmacotherapy 20060901 |
| Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study. | CNS spectrums 20060901 |
| In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. | Naunyn-Schmiedeberg's archives of pharmacology 20060901 |
| Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. | The Journal of clinical psychiatry 20060901 |
| The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. | The Journal of clinical psychiatry 20060901 |
| Switching in the era of atypical antipsychotics. An updated review. | Postgraduate medicine 20060901 |
| Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. | The Journal of pharmacology and experimental therapeutics 20060801 |
| The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. | Psychopharmacology 20060801 |
| Long-term use of atypical antipsychotics in bipolar disorder. | Pharmacotherapy 20060801 |
| Ziprasidone: efficacy and safety in patients with bipolar disorder. | Expert review of neurotherapeutics 20060801 |
| Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? | International journal of clinical practice 20060801 |
| Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. | CNS & neurological disorders drug targets 20060801 |
| Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. | PLoS medicine 20060801 |
| Advanced pediatric psychopharmacology. | Journal of child and adolescent psychopharmacology 20060801 |
| Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? | Pharmacology, biochemistry, and behavior 20060801 |
| Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060701 |
| Ziprasidone-associated pedal edema in the treatment of schizophrenia. | Progress in neuro-psychopharmacology & biological psychiatry 20060701 |
| Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20060701 |
| Interpreting the efficacy findings in the CATIE study: what clinicians should know. | CNS spectrums 20060701 |
| Implications of the CATIE trial on treatment: extrapyramidal symptoms. | CNS spectrums 20060701 |
| Metabolic findings from the CATIE trial and their relation to tolerability. | CNS spectrums 20060701 |
| Understanding the results of CATIE in the context of the field. | CNS spectrums 20060701 |
| Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. | The Journal of clinical psychiatry 20060701 |
| The metabolic effects of antipsychotic medications. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20060701 |
| Dementia with lewy bodies: therapeutic opportunities and pitfalls. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20060701 |
| Frequency of high-risk use of QT-prolonging medications. | Pharmacoepidemiology and drug safety 20060601 |
| Acute dystonia after initial doses of ziprasidone: a case report. | Progress in neuro-psychopharmacology & biological psychiatry 20060601 |
| Ziprasidone in the treatment of delayed carbon monoxide encephalopathy. | Progress in neuro-psychopharmacology & biological psychiatry 20060601 |
| Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. | Bipolar disorders 20060601 |
| Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. | Pharmacotherapy 20060601 |
| Electrocardiographic changes with ziprasidone. | Journal of the American Academy of Child and Adolescent Psychiatry 20060601 |
| Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. | Journal of the American Academy of Child and Adolescent Psychiatry 20060601 |
| Ziprasidone in bipolar disorder. | Expert opinion on pharmacotherapy 20060601 |
| Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. | Journal of child and adolescent psychopharmacology 20060601 |
| Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. | The Journal of clinical psychiatry 20060601 |
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | No to shinkei = Brain and nerve 20060601 |
| Risperidone in the treatment of bipolar mania. | Neuropsychiatric disease and treatment 20060601 |
| The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. | Neuropsychiatric disease and treatment 20060601 |
| Dose-dependent rapid-onset akathisia with aripiprazole in patients with schizoaffective disorder. | Neuropsychiatric disease and treatment 20060601 |
| Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. | Life sciences 20060522 |
| The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. | Behavioural brain research 20060515 |
| Differential effects of classical neuroleptics and a newer generation antipsychotics on the MK-801 induced behavioural primitivization in mouse. | Progress in neuro-psychopharmacology & biological psychiatry 20060501 |
| Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. | International clinical psychopharmacology 20060501 |
| Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? | Movement disorders : official journal of the Movement Disorder Society 20060501 |
| Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. | Appetite 20060501 |
| Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine. | Behavioural pharmacology 20060501 |
| Injectable atypical antipsychotics for agitation in borderline personality disorder. | Pharmacopsychiatry 20060501 |
| Rapid liquid chromatography-tandem mass spectrometry method for quantification of ziprasidone in human plasma. | Biomedical chromatography : BMC 20060401 |
| Effect of initial ziprasidone dose on length of therapy in schizophrenia. | Schizophrenia research 20060401 |
| Effect of initial ziprasidone dose on treatment persistence in schizophrenia. | Schizophrenia research 20060401 |
| Naturalistic impact of second-generation antipsychotics on weight gain. | The Annals of pharmacotherapy 20060401 |
| Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. | The American journal of psychiatry 20060401 |
| Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. | The American journal of psychiatry 20060401 |
| A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. | Journal of clinical psychopharmacology 20060401 |
| Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. | The Journal of clinical psychiatry 20060401 |
| Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. | The Journal of clinical psychiatry 20060401 |
| Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome. | The Journal of clinical psychiatry 20060401 |
| Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. | European journal of pharmacology 20060318 |
| Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. | Progress in neuro-psychopharmacology & biological psychiatry 20060301 |
| Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060301 |
| Intramuscular ziprasidone: an effective agent for sedation of the agitated ED patient. | The American journal of emergency medicine 20060301 |
| Sudden akathisia after a ziprasidone dose reduction. | The American journal of psychiatry 20060301 |
| Prescribing behavior and marketing practices. | Psychiatric services (Washington, D.C.) 20060301 |
| Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. | The Journal of nervous and mental disease 20060301 |
| Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. | Dialogues in clinical neuroscience 20060301 |
| Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities. | The American journal of geriatric pharmacotherapy 20060301 |
| An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. | The Journal of pharmacology and experimental therapeutics 20060201 |
| Emerging treatments for bipolar disorder: safety and adverse effect profiles. | The Annals of pharmacotherapy 20060201 |
| Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. | The Journal of clinical psychiatry 20060201 |
| Ziprasidone-induced acute dystonic reactions in patients with bipolar disorder. | The Journal of clinical psychiatry 20060201 |
| The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. | The Cochrane database of systematic reviews 20060125 |
| Antipsychotic drugs and schizophrenia. | The New England journal of medicine 20060119 |
| Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. | Biochemical pharmacology 20060112 |
| Amisulpride related tic-like symptoms in an adolescent schizophrenic. | Progress in neuro-psychopharmacology & biological psychiatry 20060101 |
| Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. | The pharmacogenomics journal 20060101 |
| Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. | International clinical psychopharmacology 20060101 |
| Urinary hesitancy and retention caused by ziprasidone. | International clinical psychopharmacology 20060101 |
| The effects of ziprasidone on regional c-Fos expression in the rat forebrain. | Psychopharmacology 20060101 |
| Ziprasidone- and lithium-induced neuroleptic malignant syndrome. | The Annals of pharmacotherapy 20060101 |
| Ziprasidone-induced priapism requiring surgical treatment. | European psychiatry : the journal of the Association of European Psychiatrists 20060101 |
| Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. | General hospital psychiatry 20060101 |
| Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. | Psychiatric services (Washington, D.C.) 20060101 |
| Interpreting the results of the CATIE study. | Psychiatric services (Washington, D.C.) 20060101 |
| Interpreting the results of the CATIE study. | Psychiatric services (Washington, D.C.) 20060101 |
| Interpreting the results of the CATIE study. | Psychiatric services (Washington, D.C.) 20060101 |
| Real-life switching strategies with second-generation antipsychotics. | The Journal of clinical psychiatry 20060101 |
| Methodological issues in a comparative study of ziprasidone and risperidone. | The Journal of clinical psychiatry 20060101 |
| Interactions between antiepileptic and antipsychotic drugs. | Drug safety 20060101 |
| A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. | European psychiatry : the journal of the Association of European Psychiatrists 20060101 |
| Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. | BMC psychiatry 20060101 |
| Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. | The Journal of neuropsychiatry and clinical neurosciences 20060101 |
| Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. | BMC psychiatry 20060101 |
| Update on the biological treatment of aggression. | Actas espanolas de psiquiatria 20060101 |
| Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis. | Drug safety 20060101 |
| Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. | The American journal on addictions 20060101 |
| Torsades de pointes associated with ziprasidone. | Psychosomatics 20060101 |
| Self-mutilation of fingers after cervical spinal cord injury. | Psychosomatics 20060101 |
| Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. | The Journal of neuropsychiatry and clinical neurosciences 20060101 |
| Economics of atypical antipsychotics in bipolar disorder: a review of the literature. | CNS drugs 20060101 |
| Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. | Clinical practice and epidemiology in mental health : CP & EMH 20060101 |
| Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? | Drug safety 20060101 |
| [Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment]. | Actas espanolas de psiquiatria 20060101 |
| Schizophrenia proteomics: biomarkers on the path to laboratory medicine? | Diagnostic pathology 20060101 |
| Psychiatric services in primary care settings: a survey of general practitioners in Thailand. | BMC family practice 20060101 |
| An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. | Dementia and geriatric cognitive disorders 20060101 |
| Children with schizophrenia: clinical picture and pharmacological treatment. | CNS drugs 20060101 |
| Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. | BMC neuroscience 20060101 |
| Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. | Psychopharmacology bulletin 20060101 |
| Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. | CNS drugs 20060101 |
| Adverse effects of atypical antipsychotics in the elderly: a review. | Drugs & aging 20060101 |
| Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. | Head & face medicine 20060101 |
| Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. | Clinical drug investigation 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| The bane of a silent illness: when Wilson's disease takes its course. | International journal of psychiatry in medicine 20060101 |
| Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine. | Primary care companion to the Journal of clinical psychiatry 20060101 |
| Aripiprazole: the evidence of its therapeutic impact in schizophrenia. | Core evidence 20060101 |
| An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. | Toxicology 20051215 |
| Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. | Neuropharmacology 20051201 |
| Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. | International psychogeriatrics 20051201 |
| ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. | Psychopharmacology 20051201 |
| Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. | Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20051201 |
| Drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone: an in vitro study. | Journal of clinical psychopharmacology 20051201 |
| Parkinsonism with intramuscular ziprasidone. | The American journal of psychiatry 20051201 |
| Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. | Archives of general psychiatry 20051201 |
| Overdoses and ingestions of second-generation antipsychotics in children and adolescents. | Journal of child and adolescent psychopharmacology 20051201 |
| Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. | The American journal of geriatric pharmacotherapy 20051201 |
| Combination/augmentation strategies for improving the treatment of depression. | Neuropsychiatric disease and treatment 20051201 |
| Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20051123 |
| Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. | Psychopharmacology 20051101 |
| Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine versus 5.0 mg/kg clozapine versus vehicle in a three-choice drug discrimination task. | Behavioural pharmacology 20051101 |
| Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. | Pharmacotherapy 20051101 |
| Tardive dystonia associated with ziprasidone. | The American journal of psychiatry 20051101 |
| Weight change with atypical antipsychotics in the treatment of schizophrenia. | Journal of psychopharmacology (Oxford, England) 20051101 |
| The expert consensus guideline series. Treatment of behavioral emergencies 2005. | Journal of psychiatric practice 20051101 |
| Ziprasidone therapy for post-traumatic stress disorder. | Journal of psychiatry & neuroscience : JPN 20051101 |
| Models of treatment with antipsychotics of the schizophrenic patients. | Bosnian journal of basic medical sciences 20051101 |
| From clinical research to clinical practice: a 4-year review of ziprasidone. | CNS spectrums 20051101 |
| Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. | The Journal of clinical psychiatry 20051101 |
| Applying parsimony to 'An African patient with ziprasidone intolerance'. | The Journal of clinical psychiatry 20051101 |
| [Relationships between mental and cardiac diseases]. | MMW Fortschritte der Medizin 20051020 |
| Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. | JAMA 20051019 |
| The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. | Schizophrenia research 20051015 |
| Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. | The Journal of pharmacology and experimental therapeutics 20051001 |
| Rhabdomyolysis after correction of hyponatremia in psychogenic polydipsia possibly complicated by ziprasidone. | The Annals of pharmacotherapy 20051001 |
| Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. | Journal of clinical psychopharmacology 20051001 |
| Treatment of refractory chronic daily headache with the atypical antipsychotic ziprasidone--a case series. | Cephalalgia : an international journal of headache 20051001 |
| Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. | The American journal of psychiatry 20051001 |
| Atypical antipsychotics: special formulations for acute agitation. | Journal of psychosocial nursing and mental health services 20051001 |
| Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20051001 |
| Dystonic reaction induced by ziprasidone. | Psychiatry (Edgmont (Pa. : Township)) 20051001 |
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. | The New England journal of medicine 20050922 |
| Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. | The international journal of neuropsychopharmacology 20050901 |
| [Augmenting atypical antipsychotic medications with clozapin]. | Der Nervenarzt 20050901 |
| Atypical antipsychotics produce within-session decrements on self-stimulation of the rat medial prefrontal cortex. | Frontiers in bioscience : a journal and virtual library 20050901 |
| Antipsychotic drugs and QT prolongation. | International clinical psychopharmacology 20050901 |
| The safety and tolerability of atypical antipsychotics in bipolar disorder. | Expert opinion on drug safety 20050901 |
| Ziprasidone decreases cortisol excretion in healthy subjects. | British journal of clinical pharmacology 20050901 |
| Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. | Archives of general psychiatry 20050901 |
| Atypical antipsychotics and the burden of disease. | The American journal of managed care 20050901 |
| Impact of atypical antipsychotics on outcomes of care in schizophrenia. | The American journal of managed care 20050901 |
| Best clinical practice with ziprasidone IM: update after 2 years of experience. | CNS spectrums 20050901 |
| Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20050901 |
| Atypical antipsychotics in the management of delirium: a review of the empirical literature. | Palliative & supportive care 20050901 |
| Ziprasidone treatment for posttraumatic stress disorder: 128 cases. | Psychiatry (Edgmont (Pa. : Township)) 20050901 |
| Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. | Neuropharmacology 20050801 |
| Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. | Journal of clinical psychopharmacology 20050801 |
| Safety and tolerability of emerging pharmacological treatments for bipolar disorder. | Bipolar disorders 20050801 |
| Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient. | International journal of geriatric psychiatry 20050801 |
| Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. | The American journal of psychiatry 20050801 |
| Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. | The Journal of clinical psychiatry 20050801 |
| Treatment of acute agitation in psychotic disorders. | Neuro endocrinology letters 20050801 |
| Ziprasidone and hypomania. | CNS spectrums 20050801 |
| Ziprasidone-induced tardive dyskinesia. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20050801 |
| The potential risks of commonly prescribed antipsychotics: during pregnancy and lactation. | Psychiatry (Edgmont (Pa. : Township)) 20050801 |
| The crossover approach to switching antipsychotics: what is the evidence? | Schizophrenia research 20050715 |
| Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism. | Brain research 20050712 |
| Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. | Drug metabolism and disposition: the biological fate of chemicals 20050701 |
| Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. | International clinical psychopharmacology 20050701 |
| The highest intentional ziprasidone overdose was not fatal. | Acta psychiatrica Scandinavica 20050701 |
| Cerebral cortical gray expansion associated with two second-generation antipsychotics. | Biological psychiatry 20050701 |
| Methodological concerns in a trial of ziprasidone and olanzapine. | The American journal of psychiatry 20050701 |
| Methodological concerns in a trial of ziprasidone and olanzapine. | The American journal of psychiatry 20050701 |
| Higher than Physician's Desk Reference (US) doses on atypical antipsychotics. | Expert opinion on drug safety 20050701 |
| A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. | The Journal of clinical psychiatry 20050701 |
| Three-year experience with ziprasidone exposures. | The American journal of emergency medicine 20050701 |
| Modern antipsychotic drugs: a critical overview. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050621 |
| Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. | Pharmacoepidemiology and drug safety 20050601 |
| Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. | Psychopharmacology 20050601 |
| Antipsychotic drug-induced weight gain: development of an animal model. | International journal of obesity (2005) 20050601 |
| Atypical antipsychotics for bipolar disorder. | The Psychiatric clinics of North America 20050601 |
| Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. | Journal of clinical pharmacology 20050601 |
| An African patient with ziprasidone intolerance. | The Journal of clinical psychiatry 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. | Drug metabolism and pharmacokinetics 20050601 |
| The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. | Neuro endocrinology letters 20050601 |
| Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? | European archives of psychiatry and clinical neuroscience 20050601 |
| Bipolar disorder. | Clinical evidence 20050601 |
| Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. | Neuropsychiatric disease and treatment 20050601 |
| Atypical presentations of atypical antipsychotics. | Psychiatry (Edgmont (Pa. : Township)) 20050601 |
| Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. | Behavioural brain research 20050528 |
| FDA warns antipsychotic drugs may be risky for elderly. | JAMA 20050525 |
| Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. | Brain research 20050510 |
| Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. | Psychopharmacology 20050501 |
| Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. | Psychopharmacology 20050501 |
| [Haematological abnormalities during treatment with atypical antipsychotics]. | Psychiatrische Praxis 20050501 |
| Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. | Diabetes 20050501 |
| Ziprasidone pretreatment attenuates the lethal effects of cocaine in a mouse model. | Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20050501 |
| Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. | Psychopharmacology 20050401 |
| Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. | Therapeutic drug monitoring 20050401 |
| Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? | Human psychopharmacology 20050401 |
| Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? | Current opinion in pediatrics 20050401 |
| Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. | Journal of child and adolescent psychopharmacology 20050401 |
| Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. | Journal of psychopharmacology (Oxford, England) 20050301 |
| Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. | International clinical psychopharmacology 20050301 |
| D2-blockade and possible ziprasidone-induced galactorrhea. | International clinical psychopharmacology 20050301 |
| Ziprasidone-induced acute dystonia. | The American journal of psychiatry 20050301 |
| Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders. | CNS spectrums 20050301 |
| The treatment of mixed states and the risk of switching to depression. | European psychiatry : the journal of the Association of European Psychiatrists 20050301 |
| Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. | Psychopharmacology 20050201 |
| On the trail of a cognitive enhancer for the treatment of schizophrenia. | Progress in neuro-psychopharmacology & biological psychiatry 20050201 |
| New onset of diabetes mellitus with ziprasidone: a case report. | The Journal of clinical psychiatry 20050201 |
| Ziprasidone-induced galactorrhea: a case report. | Neuro endocrinology letters 20050201 |
| Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. | Expert opinion on pharmacotherapy 20050201 |
| The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. | European journal of pharmacology 20050104 |
| Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. | Journal of the American Academy of Child and Adolescent Psychiatry 20050101 |
| Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. | Progress in neuro-psychopharmacology & biological psychiatry 20050101 |
| Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. | BMC psychiatry 20050101 |
| Managing bipolar disorder in the elderly: defining the role of the newer agents. | Drugs & aging 20050101 |
| Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole. | Drugs of today (Barcelona, Spain : 1998) 20050101 |
| Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling. | BMC bioinformatics 20050101 |
| Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. | The Journal of clinical psychiatry 20050101 |
| Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. | General hospital psychiatry 20050101 |
| Blood dyscrasia with quetiapine and ziprasidone. | Psychosomatics 20050101 |
| Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. | Clinical neuropharmacology 20050101 |
| Ziprasidone-associated mania: a review and report of 2 additional cases. | Clinical neuropharmacology 20050101 |
| Atypical antipsychotic therapy and hyperlipidemia: a review. | Essential psychopharmacology 20050101 |
| 12,800-mg ziprasidone overdose without significant ECG changes. | General hospital psychiatry 20050101 |
| Possible serotonin syndrome with citalopram following cross-titration of clozapine to ziprasidone. | General hospital psychiatry 20050101 |
| The dosing of atypical antipsychotics. | Psychosomatics 20050101 |
| Pharmacological management of acute agitation. | Drugs 20050101 |
| Tinnitus dopaminergic pathway. Ear noises treatment by dopamine modulation. | Medical hypotheses 20050101 |
| Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current. | Journal of pharmacological and toxicological methods 20050101 |
| Atypical antipsychotics: newer options for mania and maintenance therapy. | Bipolar disorders 20050101 |
| Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review. | CNS drugs 20050101 |
| Spotlight on olanzapine in bipolar I disorder. | CNS drugs 20050101 |
| Use of ziprasidone in parkinsonian patients with psychosis. | Clinical neuropharmacology 20050101 |
| Ziprasidone for agitation or psychosis in dementia: four cases. | International journal of psychiatry in medicine 20050101 |
| Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. | CNS drugs 20050101 |
| The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. | Medical hypotheses 20050101 |
| Ziprasidone and hypokalemia: a case of 2 predisposing factors for QTc prolongation without development of torsades de pointes. | Primary care companion to the Journal of clinical psychiatry 20050101 |
| [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics]. | Revue medicale de Liege 20050101 |
| A typical mood stabilizers: a 'typical role for atypical antipsychotics. | Acta psychiatrica Scandinavica. Supplementum 20050101 |
| Schizophrenia, antipsychotic drugs, and cardiovascular disease. | The Journal of clinical psychiatry 20050101 |
| Dealing with the delirium dilemma. | Critical care (London, England) 20050101 |
| Ziprasidone: from pharmacology to the clinical practice. One year of experience. | Actas espanolas de psiquiatria 20050101 |
| [A new approach to the treatment of delirium: atypical antipsychotics]. | Turk psikiyatri dergisi = Turkish journal of psychiatry 20050101 |
| Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. | Rapid communications in mass spectrometry : RCM 20050101 |
| Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. | Clinical pharmacokinetics 20050101 |
| Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. | Clinical neuropharmacology 20050101 |
| Ziprasidone and psychosis in Parkinson disease. | Clinical neuropharmacology 20050101 |
| Tardive nocturnal akathisia due to clozapine treatment. | International journal of psychiatry in medicine 20050101 |
| Ziprasidone overdose: cardiac safety. | Actas espanolas de psiquiatria 20050101 |
| Use of atypical antipsychotics in refractory depression and anxiety. | The Journal of clinical psychiatry 20050101 |
| Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients. | Clinical neuropharmacology 20050101 |
| Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. | BMC medicine 20050101 |
| Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. | PharmacoEconomics 20050101 |
| Atypicality of atypical antipsychotics. | Primary care companion to the Journal of clinical psychiatry 20050101 |
| [Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities]. | Przeglad lekarski 20050101 |
| Psychotropic drug utilization pattern among patients with schizophrenia. | Indian journal of psychiatry 20050101 |
| Factitious schizophrenia. | Indian journal of psychiatry 20050101 |
| Pharmacology of antipsychotics in the elderly: a focus on atypicals. | Journal of the American Geriatrics Society 20041201 |
| Optimizing atypical antipsychotic treatment strategies in the elderly. | Journal of the American Geriatrics Society 20041201 |
| An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. | Controlled clinical trials 20041201 |
| Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. | Progress in neuro-psychopharmacology & biological psychiatry 20041201 |
| Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. | The Journal of clinical psychiatry 20041201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20041201 |
| Metabolic risk during antipsychotic treatment. | Clinical therapeutics 20041201 |
| [Misdiagnosed PTSD and zeldox pharmacotherapy in case of a political prisoner]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20041201 |
| Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. | European journal of pharmacology 20041128 |
| Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. | The Journal of clinical psychiatry 20041101 |
| [Risk of QTc prolongation due to combination of ziprasidone and quetiapine]. | Psychiatrische Praxis 20041101 |
| [QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey]. | Psychiatrische Praxis 20041101 |
| Ziprasidone: first year experience in a hospital setting. | Journal of psychiatric practice 20041101 |
| Tardive dyskinesia in 2 patients treated with ziprasidone. | Journal of psychiatry & neuroscience : JPN 20041101 |
| Treatment of bipolar mania with atypical antipsychotics. | Expert review of neurotherapeutics 20041101 |
| Maintenance therapy for bipolar disorder: current and future management options. | Expert review of neurotherapeutics 20041101 |
| Acute dystonic reaction with moderate-dose ziprasidone. | Journal of clinical psychopharmacology 20041001 |
| Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. | Journal of clinical psychopharmacology 20041001 |
| The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research. | Bipolar disorders 20041001 |
| Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. | The American journal of psychiatry 20041001 |
| Prolactin elevation with ziprasidone. | The American journal of psychiatry 20041001 |
| Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. | CNS spectrums 20041001 |
| [Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease]. | Revista de neurologia 20041001 |
| The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. | Postgraduate medicine 20041001 |
| [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20041001 |
| The effects of antipsychotic therapy on serum lipids: a comprehensive review. | Schizophrenia research 20040901 |
| Intravenous ziprasidone for treatment of delirium in the intensive care unit. | Anesthesiology 20040901 |
| Dosage and administration issues of antipsychotic agents (and adjunctive medicines) in the acute stabilization of psychoses. | CNS spectrums 20040901 |
| Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. | The Journal of clinical psychiatry 20040901 |
| Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. | The Journal of clinical psychiatry 20040901 |
| Behavioral disturbances in Parkinson's disease. | Dialogues in clinical neuroscience 20040901 |
| [Ziprasidone and dementia]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20040826 |
| [Psychotropics and weight gain]. | Praxis 20040825 |
| Physical health monitoring of patients with schizophrenia. | The American journal of psychiatry 20040801 |
| Ziprasidone and mania. | The American journal of psychiatry 20040801 |
| Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. | Movement disorders : official journal of the Movement Disorder Society 20040801 |
| [Non-information from a drug industry]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20040701 |
| [Ziprasidone-augmentation of clozapine]. | Psychiatrische Praxis 20040701 |
| Antipsychotic treatment of psychosis associated with multiple sclerosis. | Progress in neuro-psychopharmacology & biological psychiatry 20040701 |
| The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. | The Journal of clinical psychiatry 20040701 |
| Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. | Clinical therapeutics 20040701 |
| No significant QTc interval changes with high-dose ziprasidone: a case series. | Journal of psychiatric practice 20040701 |
| Pharmacological treatment strategies for schizophrenia. | Expert review of neurotherapeutics 20040701 |
| Evidence-based pharmacotherapy of schizophrenia. | The international journal of neuropsychopharmacology 20040601 |
| QTc prolongation in multiple drug overdose. | Journal of clinical psychopharmacology 20040601 |
| Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. | Human psychopharmacology 20040601 |
| Ziprasidone-induced lupus erythematosus. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20040601 |
| Occupancy of agonist drugs at the 5-HT1A receptor. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040501 |
| Improvement in prosocial functioning after a switch to ziprasidone treatment. | CNS spectrums 20040501 |
| A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. | The American journal of psychiatry 20040501 |
| Ziprasidone for sedation of the agitated ED patient. | The American journal of emergency medicine 20040501 |
| Quetiapine-associated acute dystonia. | The Annals of pharmacotherapy 20040401 |
| Use of ziprasidone to treat bipolar-associated catatonia. | Bipolar disorders 20040401 |
| Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. | Current drug targets 20040401 |
| Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. | Human psychopharmacology 20040401 |
| Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations. | Biomedical chromatography : BMC 20040401 |
| The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. | The Journal of clinical psychiatry 20040401 |
| Atypical antipsychotics and diabetes mellitus. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20040401 |
| Ziprasidone and mania. | Journal of the American Academy of Child and Adolescent Psychiatry 20040401 |
| Dose response and dose equivalence of antipsychotics. | Journal of clinical psychopharmacology 20040401 |
| Therapeutic monitoring of new antipsychotic drugs. | Therapeutic drug monitoring 20040401 |
| [Ziprasidone. A new second-generation antipsychotic agent]. | Ugeskrift for laeger 20040329 |
| Selective optimization of side activities: another way for drug discovery. | Journal of medicinal chemistry 20040311 |
| Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. | Psychopharmacology 20040301 |
| Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. | The American journal of psychiatry 20040301 |
| [Hypomania induced by Ziprasidone]. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20040301 |
| [Paralytic ileus during haloperidol therapy]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20040301 |
| Evaluating the reconstitution of intramuscular ziprasidone (Geodon) into solution. | Annals of emergency medicine 20040301 |
| Ziprasidone: a novel psychotropic with unique properties. | Expert review of neurotherapeutics 20040301 |
| Treatment-refractory schizophrenia. | Dialogues in clinical neuroscience 20040301 |
| Sex-dependent modulation of treatment response. | Dialogues in clinical neuroscience 20040301 |
| A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. | Journal of clinical psychopharmacology 20040201 |
| Selection of atypical antipsychotics for the management of schizophrenia. | The Annals of pharmacotherapy 20040201 |
| Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. | Current medicinal chemistry 20040201 |
| Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. | Current medicinal chemistry 20040201 |
| A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. | Current medicinal chemistry 20040201 |
| Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. | Current medicinal chemistry 20040201 |
| New antipsychotics and schizophrenia: a review on efficacy and side effects. | Current medicinal chemistry 20040201 |
| Aripiprazole, a novel atypical antipsychotic drug. | Pharmacotherapy 20040201 |
| Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. | The Journal of clinical psychiatry 20040201 |
| Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. | Schizophrenia research 20040201 |
| Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040125 |
| [Current pharmacotherapy of schizophrenia]. | Orvosi hetilap 20040118 |
| Ziprasidone-related tardive dyskinesia. | The American journal of psychiatry 20040101 |
| The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. | The Journal of clinical psychiatry 20040101 |
| Hypomanic episodes after receiving ziprasidone: an unintended 'on-off-on' course of treatment. | The Journal of clinical psychiatry 20040101 |
| Ziprasidone in Parkinson's disease psychosis. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20040101 |
| Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. | Paediatric drugs 20040101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040101 |
| Using antipsychotic agents in older patients. | The Journal of clinical psychiatry 20040101 |
| Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. | Drugs 20040101 |
| The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. | International clinical psychopharmacology 20040101 |
| Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. | The Journal of clinical psychiatry 20040101 |
| Atypical antipsychotics in the treatment of children and adolescents: clinical applications. | The Journal of clinical psychiatry 20040101 |
| Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. | BMC psychiatry 20040101 |
| Ziprasidone treatment of two adolescents with psychosis. | Journal of child and adolescent psychopharmacology 20040101 |
| The case for atypical antipsychotics in bipolar disorder. | Perspectives in psychiatric care 20040101 |
| Atypical antipsychotics in the treatment of affective symptoms: a review. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20040101 |
| Clinical utilization of atypical antipsychotics in pregnancy and lactation. | The Annals of pharmacotherapy 20040101 |
| Dose response and atypical antipsychotics in schizophrenia. | CNS drugs 20040101 |
| The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting. | Journal of the American Medical Directors Association 20040101 |
| Ziprasidone and weight gain. | Clinical neuropharmacology 20040101 |
| Drug therapy in schizophrenia. | Current pharmaceutical design 20040101 |
| Side effects of atypical antipsychotic drugs. | Current pharmaceutical design 20040101 |
| Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? | Current pharmaceutical design 20040101 |
| Atypical antipsychotic induced weight gain: pathophysiology and management. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20040101 |
| Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. | Drugs 20040101 |
| The utility of intramuscular ziprasidone in the management of acute psychotic agitation. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20040101 |
| Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20040101 |
| Impact of atypical antipsychotics on quality of life in patients with schizophrenia. | CNS drugs 20040101 |
| Olanzapine: a review of its use in the management of bipolar I disorder. | Drugs 20040101 |
| Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. | Drug safety 20040101 |
| Pharmacotherapy of pervasive developmental disorders in children and adolescents. | CNS drugs 20040101 |
| Second-generation antipsychotic medications in children and adolescents. | Journal of child and adolescent psychopharmacology 20040101 |
| Intramuscular ziprasidone for acute agitation in adolescents. | Journal of child and adolescent psychopharmacology 20040101 |
| Ziprasidone monotherapy in pediatric bipolar disorder. | Journal of child and adolescent psychopharmacology 20040101 |
| The use of two neuroleptics to treat bipolar illness in two children. | Journal of child and adolescent psychopharmacology 20040101 |
| Intramuscular ziprasidone in youth: a retrospective chart review. | Journal of child and adolescent psychopharmacology 20040101 |
| Sexuality and schizophrenia: a review. | Schizophrenia bulletin 20040101 |
| Atypical antipsychotics: sleep, sedation, and efficacy. | Primary care companion to the Journal of clinical psychiatry 20040101 |
| The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. | Metabolic syndrome and related disorders 20040101 |
| Ziprasidone and its association with sudden cardiac death - a case report. | Indian journal of psychiatry 20040101 |
| Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. | Journal of clinical psychopharmacology 20031201 |
| Extrapyramidal symptoms in children on atypical antipsychotic drugs. | Journal of clinical psychopharmacology 20031201 |
| Relationship of atypical antipsychotics with development of diabetes mellitus. | The Annals of pharmacotherapy 20031201 |
| Improvement in behaviour and attention in an autistic patient treated with ziprasidone. | The Australian and New Zealand journal of psychiatry 20031201 |
| Expert consensus-based medication-use evaluation criteria for atypical antipsychotic drugs. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20031201 |
| Ziprasidone in Huntington's disease: the first case reports. | Journal of psychopharmacology (Oxford, England) 20031201 |
| Ziprasidone--not an option for serotonin syndrome. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20031125 |
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | British journal of cancer 20031117 |
| Ziprasidone: Test your drug IQ. | Nursing 20031101 |
| Mania from dose-related ziprasidone augmentation of an SSRI. | The Journal of clinical psychiatry 20031101 |
| Management of acute psychosis: from emergency to stabilization. | CNS spectrums 20031101 |
| Beyond control of acute exacerbation: enhancing affective and cognitive outcomes. | CNS spectrums 20031101 |
| Ziprasidone for dementia in elderly patients: case review. | Journal of psychiatric practice 20031101 |
| Schizophrenia, VI: Treatments. | The American journal of psychiatry 20031001 |
| Muscarinic mechanisms of antipsychotic atypicality. | Progress in neuro-psychopharmacology & biological psychiatry 20031001 |
| Serotonin receptors: their key role in drugs to treat schizophrenia. | Progress in neuro-psychopharmacology & biological psychiatry 20031001 |
| Metabolic drug interactions with new psychotropic agents. | Fundamental & clinical pharmacology 20031001 |
| Ziprasidone mesylate (Geodon for injection): the first injectable atypical antipsychotic medication. | Proceedings (Baylor University. Medical Center) 20031001 |
| Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. | Naunyn-Schmiedeberg's archives of pharmacology 20030901 |
| Possible ziprasidone-induced mania. | Journal of the American Academy of Child and Adolescent Psychiatry 20030901 |
| Ziprasidone-induced oculogyric crisis. | Journal of the American Academy of Child and Adolescent Psychiatry 20030901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030901 |
| Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. | Psychopharmacology 20030801 |
| Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. | Journal of the American Academy of Child and Adolescent Psychiatry 20030801 |
| The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. | Schizophrenia research 20030701 |
| Side effects of ziprasidone. | The American journal of psychiatry 20030701 |
| Pharmacological management of agitation in emergency settings. | Emergency medicine journal : EMJ 20030701 |
| Antipsychotic medication and seizures: a review. | Drugs of today (Barcelona, Spain : 1998) 20030701 |
| Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells. | FEBS letters 20030619 |
| [Treatment of young people with atypical antipsychotic agents]. | Ugeskrift for laeger 20030602 |
| Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. | Bipolar disorders 20030601 |
| Use of atypical antipsychotic drugs in patients with dementia. | American family physician 20030601 |
| Chlorpromazine equivalent doses for the newer atypical antipsychotics. | The Journal of clinical psychiatry 20030601 |
| Ziprasidone metabolism, aldehyde oxidase, and clinical implications. | Journal of clinical psychopharmacology 20030601 |
| Efficacy of atypical antipsychotics in mood disorders. | Journal of clinical psychopharmacology 20030601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030601 |
| Ziprasidone in autism. | Journal of the American Academy of Child and Adolescent Psychiatry 20030601 |
| The relevance of prolonged QTc measurement to pediatric psychopharmacology. | Journal of the American Academy of Child and Adolescent Psychiatry 20030601 |
| Advances in pharmacotherapy of psychotic disorders in the elderly. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20030601 |
| New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. | Lancet (London, England) 20030510 |
| A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. | Psychopharmacology 20030501 |
| Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. | The Journal of clinical psychiatry 20030501 |
| Ziprasidone substitution in a patient with risperidone-induced hyperprolactinemia. | Journal of psychiatric practice 20030501 |
| Atypical antipsychotics and mood stabilization in bipolar disorder. | Psychopharmacology 20030401 |
| Psychic akathisia. | Journal of clinical psychopharmacology 20030401 |
| Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907. | Neuropharmacology 20030401 |
| Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. | The American journal of psychiatry 20030401 |
| H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20030301 |
| Interactions between the cytochrome P450 system and the second-generation antipsychotics. | Journal of psychiatry & neuroscience : JPN 20030301 |
| A case series of ziprasidone overdoses. | Veterinary and human toxicology 20030301 |
| The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. | Journal of psychopharmacology (Oxford, England) 20030301 |
| Detection of proarrhythmia in the female rabbit heart: blinded validation. | Journal of cardiovascular electrophysiology 20030301 |
| Mania associated with initiation of ziprasidone. | The Journal of clinical psychiatry 20030301 |
| alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. | European journal of pharmacology 20030221 |
| Ziprasidone augmentation of clozapine in 11 patients. | The Journal of clinical psychiatry 20030201 |
| Ziprasidone-associated mania: a case series and review of the mechanism. | Bipolar disorders 20030201 |
| Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. | Journal of the National Medical Association 20030201 |
| Pharmacotherapy of behavioral and psychological symptoms of dementia: a review of atypical antipsychotics. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20030201 |
| Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs. | The Journal of pharmacology and experimental therapeutics 20030101 |
| Ziprasidone-associated galactorrhea in a female teenager. | Journal of the American Academy of Child and Adolescent Psychiatry 20030101 |
| Sexual dysfunction and antipsychotic treatment. | Psychoneuroendocrinology 20030101 |
| A review of the effect of atypical antipsychotics on weight. | Psychoneuroendocrinology 20030101 |
| Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. | The Journal of clinical psychiatry 20030101 |
| Prolonged erections associated with ziprasidone treatment: a case report. | The Journal of clinical psychiatry 20030101 |
| Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. | Drugs 20030101 |
| Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. | Journal of toxicology. Clinical toxicology 20030101 |
| Fatalities associated with therapeutic use and overdose of atypical antipsychotics. | CNS drugs 20030101 |
| Ziprasidone in the management of schizophrenia : the QT interval issue in context. | CNS drugs 20030101 |
| Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. | Journal of toxicology. Clinical toxicology 20030101 |
| Treatment of psychosis in Parkinson's disease: safety considerations. | Drug safety 20030101 |
| [Benzodiazepines, typical and atypical antipsychotics in the management of acute agitation: a review]. | Turk psikiyatri dergisi = Turkish journal of psychiatry 20030101 |
| Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. | The Journal of international medical research 20030101 |
| The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. | Schizophrenia bulletin 20030101 |
| QTc prolongation due to propranolol overdose. | International journal of psychiatry in medicine 20030101 |
| New generation antipsychotics for first episode schizophrenia. | The Cochrane database of systematic reviews 20030101 |
| Ziprasidone-induced Pisa syndrome after clozapine treatment. | The Journal of neuropsychiatry and clinical neurosciences 20030101 |
| Choice of maintenance medication for schizophrenia. | The Journal of clinical psychiatry 20030101 |
| Similarities and differences among antipsychotics. | The Journal of clinical psychiatry 20030101 |
| Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. | Bipolar disorders 20030101 |
| Cardiotoxicity associated with intentional Ziprasidone and bupropion overdose. | Journal of toxicology. Clinical toxicology 20030101 |
| Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management. | The Journal of clinical psychiatry 20030101 |
| The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. | The Journal of clinical psychiatry 20030101 |
| Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. | The Journal of clinical psychiatry 20030101 |
| Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. | The Journal of clinical psychiatry 20030101 |
| Maintaining symptom control: review of ziprasidone long-term efficacy data. | The Journal of clinical psychiatry 20030101 |
| Ziprasidone and cognition: the evolving story. | The Journal of clinical psychiatry 20030101 |
| Tolerability of ziprasidone: an expanding perspective. | The Journal of clinical psychiatry 20030101 |
| Clinical case presentation: therapeutic challenges in adolescent-onset bipolar disorder. | Journal of child and adolescent psychopharmacology 20030101 |
| Conventional and atypical antipsychotics in the elderly : a review. | Clinical drug investigation 20030101 |
| Weight gain associated with atypical antipsychotic drugs: mechanisms and management. | Expert review of neurotherapeutics 20030101 |
| Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. | Brain research 20021220 |
| Neuroleptic Malignant Syndrome with ziprasidone. | Journal of clinical psychopharmacology 20021201 |
| Aripiprazole: profile on efficacy and safety. | Expert opinion on pharmacotherapy 20021201 |
| Recent developments in pharmacotherapy for the acutely psychotic patient. | Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association 20021201 |
| A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. | The Journal of clinical psychiatry 20021201 |
| Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern. | Dialogues in clinical neuroscience 20021201 |
| Optimizing dosing in atypical neuroleptic monotherapy. | Dialogues in clinical neuroscience 20021201 |
| Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. | Brain research 20021129 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021101 |
| Antipsychotics: impact on prolactin levels. | Expert opinion on pharmacotherapy 20021001 |
| A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. | International clinical psychopharmacology 20020901 |
| Ziprasidone alternative for olanzapine-induced hyperglycemia. | The American journal of psychiatry 20020901 |
| Continuum of care: stabilizing the acutely agitated patient. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020901 |
| Clinical issues associated with maintenance treatment of patients with schizophrenia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020901 |
| Comprehensive understanding of schizophrenia and its treatment. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020901 |
| A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. | European journal of pharmacology 20020816 |
| Ziprasidone and migraine headache. | The American journal of psychiatry 20020801 |
| Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. | The American journal of psychiatry 20020801 |
| Tardive dyskinesia and ziprasidone. | The American journal of psychiatry 20020801 |
| Case series: use of ziprasidone for maladaptive symptoms in youths with autism. | Journal of the American Academy of Child and Adolescent Psychiatry 20020801 |
| Priapism associated with two atypical antipsychotic agents. | Pharmacotherapy 20020801 |
| Mood stabilization and the role of antipsychotics. | International clinical psychopharmacology 20020801 |
| Choosing an atypical antipsychotic. | International clinical psychopharmacology 20020801 |
| Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors. | Psychopharmacology 20020701 |
| The value of atypical antipsychotics in the treatment of schizophrenia. | Managed care (Langhorne, Pa.) 20020701 |
| New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. | Current opinion in investigational drugs (London, England : 2000) 20020701 |
| Brief report on Ziprasidone. | Mymensingh medical journal : MMJ 20020701 |
| 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. | Brain research 20020607 |
| Overdose of ziprasidone. | The American journal of psychiatry 20020601 |
| Prolongation of QTc interval and antipsychotics. | The American journal of psychiatry 20020601 |
| A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. | The Journal of clinical psychiatry 20020601 |
| [Psychopharmacological treatment of bipolar disease]. | Ugeskrift for laeger 20020506 |
| [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain]. | MMW Fortschritte der Medizin 20020506 |
| Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20020501 |
| Ziprasidone: the fifth atypical antipsychotic. | The Annals of pharmacotherapy 20020501 |
| Experience with ziprasidone. | Journal of the American Academy of Child and Adolescent Psychiatry 20020501 |
| The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. | Journal of clinical psychopharmacology 20020401 |
| Ziprasidone induction of hypomania in depression? | The American journal of psychiatry 20020401 |
| Current status of antipsychotic treatment. | Current drug targets. CNS and neurological disorders 20020401 |
| Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20020301 |
| Schizophrenia: genesis, receptorology and current therapeutics. | Current medicinal chemistry 20020301 |
| Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20020301 |
| Best clinical practice with ziprasidone: update after one year of experience. | Journal of psychiatric practice 20020301 |
| Atypical antipsychotics: mechanism of action. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20020201 |
| Effects of newer antipsychotics on extrapyramidal function. | CNS drugs 20020101 |
| Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. | Journal of psychiatric research 20020101 |
| Ziprasidone hydrochloride. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020101 |
| Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. | Clinical therapeutics 20020101 |
| Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. | Epilepsia 20020101 |
| Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. | The Journal of clinical psychiatry 20020101 |
| Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. | The Journal of clinical psychiatry 20020101 |
| Ziprasidone treatment of delirium. | Psychosomatics 20020101 |
| Pharmacological treatment of psychotic agitation. | CNS drugs 20020101 |
| Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. | CNS drugs 20020101 |
| Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. | Drugs 20020101 |
| The role of atypical antipsychotics in the treatment of delirium. | Psychosomatics 20020101 |
| The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. | BMC psychiatry 20020101 |
| Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. | Drugs 20020101 |
| Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. | CNS drugs 20020101 |
| Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. | Harvard review of psychiatry 20020101 |
| Cataract occurrence with antipsychotic drugs. | Psychosomatics 20020101 |
| New drugs 2002, part 1. | Nursing 20020101 |
| Antipsychotic-induced hyperprolactinemia and sexual dysfunction. | Psychopharmacology bulletin 20020101 |
| Safety and tolerability: how do newer generation 'atypical' antipsychotics compare? | The Psychiatric quarterly 20020101 |
| Clinical significance of drug binding, protein binding, and binding displacement drug interactions. | Psychopharmacology bulletin 20020101 |
| Investigation of the potential of clozapine to cause torsade de pointes. | Adverse drug reactions and toxicological reviews 20020101 |
| [Schizoaffective disorder: clinical symptoms and present-day approach to treatment]. | Medicina (Kaunas, Lithuania) 20020101 |
| Comparing the side effect profile of the atypical antipsychotics. | West African journal of medicine 20020101 |
| 'Atypical' antipsychotics: where does ziprasidone fit? | Expert review of neurotherapeutics 20020101 |
| Treatments for chronic psychosis. | Dialogues in clinical neuroscience 20011201 |
| Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. | European journal of pharmacology 20011102 |
| Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. | The American journal of psychiatry 20011101 |
| Cardiovascular side effects of novel antipsychotics. | CNS spectrums 20011101 |
| Ziprasidone update. | Journal of psychiatric practice 20011101 |
| Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. | European journal of pharmacology 20011005 |
| Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | The Journal of pharmacology and experimental therapeutics 20011001 |
| Antipsychotic medication: effects on regulation of glucose and lipids. | Expert opinion on pharmacotherapy 20011001 |
| Ziprasidone: profile on safety. | Expert opinion on pharmacotherapy 20011001 |
| Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20010901 |
| Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. | European journal of pharmacology 20010817 |
| Use of atypical antipsychotics in mood disorders. | Current opinion in investigational drugs (London, England : 2000) 20010701 |
| Ziprasidone (Geodon) for schizophrenia. | The Medical letter on drugs and therapeutics 20010611 |
| Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT. | Neuropharmacology 20010601 |
| Ziprasidone, a new atypical antipsychotic drug. | Pharmacotherapy 20010601 |
| Ziprasidone approved. | The Harvard mental health letter 20010601 |
| Ziprasidone: a new atypical antipsychotic. | Expert opinion on pharmacotherapy 20010601 |
| Psychosis in children: diagnosis and treatment. | Dialogues in clinical neuroscience 20010601 |
| Ziprasidone hydrochloride approved for treatment of schizophrenia, but with major warning. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010501 |
| Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. | Psychopharmacology 20010501 |
| The apparent effects of ziprasidone on plasma lipids and glucose. | The Journal of clinical psychiatry 20010501 |
| Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20010401 |
| The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? | Journal of psychopharmacology (Oxford, England) 20010301 |
| Ziprasidone: a new atypical antipsychotic. | Journal of psychiatric practice 20010301 |
| Current and novel approaches to the drug treatment of schizophrenia. | Journal of medicinal chemistry 20010215 |
| Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies. | Journal of clinical psychopharmacology 20010201 |
| Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. | European journal of pharmacology 20010126 |
| Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. | Annual review of medicine 20010101 |
| Bodyweight gain with atypical antipsychotics. A comparative review. | Drug safety 20010101 |
| Antipsychotic medications and the elderly: effects on cognition and implications for use. | Drugs & aging 20010101 |
| Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. | The Journal of clinical psychiatry 20010101 |
| Barriers to progress--the impact of tolerability problems. | International clinical psychopharmacology 20010101 |
| Sustaining short-term gains for future progress. | International clinical psychopharmacology 20010101 |
| The pharmacology of weight gain with antipsychotics. | The Journal of clinical psychiatry 20010101 |
| Tourette syndrome: clinical characteristics and current management strategies. | Paediatric drugs 20010101 |
| Psychopharmacology news. | Journal of child and adolescent psychopharmacology 20010101 |
| New schizophrenia drug. | FDA consumer 20010101 |
| Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. | Pharmacology, biochemistry, and behavior 20010101 |
| Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. | Current opinion in investigational drugs (London, England : 2000) 20010101 |
| Emerging options in the treatment of bipolar disorders. | Drugs 20010101 |
| Review of atypical antipsychotics and weight gain. | The Journal of clinical psychiatry 20010101 |
| Med-psych drug-drug interactions update. | Psychosomatics 20010101 |
| Focus on ziprasidone. | Current medical research and opinion 20010101 |
| Pharmacological options for the treatment of Tourette's disorder. | Drugs 20010101 |
| Tolerability profile of atypical antipsychotics in children and adolescents. | Paediatric drugs 20010101 |
| Hyperglycemia and antipsychotic medications. | The Journal of clinical psychiatry 20010101 |
| Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. | Psychopharmacology bulletin 20010101 |
| Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. | The Journal of pharmacology and experimental therapeutics 20001001 |
| Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. | European journal of pharmacology 19980821 |
| Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 19980201 |
| Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. | Psychopharmacology 19960301 |
| Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. | The Journal of pharmacology and experimental therapeutics 19951001 |
| Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. | European journal of pharmacology 19950905 |